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ABSTRACT 
 
Osteoporosis is a significant public health problem in the U.S.  It not only affects 
the physical well-being of the older women but also creates a substantial financial burden 
for the health care system.  The mainstay of osteoporosis medications is bisphosphonate 
treatment of which alendronate and risedronate are the most commonly prescribed in 
clinical practice.  However, there have been no head-to-head randomized controlled trials 
(RCTs) evaluating the effects of these two bisphosphonates on fracture outcomes. 
In the absence of RCTs, observational studies are necessary to provide alternative 
evidence on the comparative effectiveness between alendronate and risedronate on 
fracture outcomes.  However, existing observational studies have provided inconclusive 
results partially due to residual confounding from unobserved variables such as patients’ 
health status or behavior.  IV analysis may be one method to address unmeasured 
confounding bias in observational studies.  While it has not been applied in 
bisphosphonate research, it has been used in research on a variety of other prescription 
medications.  
In this dissertation, we applied the IV approach with an IV, date of generic 
alendronate availability, to evaluate the comparative effectiveness between alendronate 
and risedronate using observational data.  This dissertation improved current research in 
several ways.  First, we extended the IV approach to research on bisphosphonates.  
Second, compared with the current observational studies on bisphosphonates, this 
dissertation may more accurately estimate the relative effects between alendronate and 
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risedronate because IV analysis is not subject to unmeasured confounding bias.  Third, 
the study results extended the current evidence of the comparative effectiveness between 
the two most commonly prescribed bisphosphonates.  Finally, we proposed and provided 
empirical evidence of a new IV that might be used for future prescription drug research. 
The finding of this dissertation can be summarized from three aspects.  First, we 
found that the evidence supported the validity of the date of generic availability as an IV 
in the study of bisphosphonates.  Second, applying IV approach to study the comparative 
effectiveness of alendronate and risedronate, we found that alendronate and risedronate 
were comparable to reduce the risk of 12-month non-vertebral fractures in older women.  
Since generic alendronate is availability on the market while generic risedronate is not, 
promoting the use of alendronate may help reduce the healthcare cost and not sacrifice 
the clinical effectiveness.  Finally, by comparing the proposed IV with a popular IV- 
physician preference, we found that both the calendar time IV based on the date of 
generic availability and the physician preference appeared to be valid.  It might be 
practically easier to use the calendar time IV than the physician preference IV.  
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1.1 Specific Aims 
The purpose of this dissertation was to investigate the comparative effectiveness 
of two bisphosphonates (alendronate and risedronate) on the risk of non-vertebral 
fractures in women 50 years of age or older using an instrumental variables (IV) 
approach. 
Bisphosphonate therapy is the primary pharmacologic treatment for 
osteoporosis.1, 2  Among all bisphosphonates, alendronate and risedronate are the most 
commonly prescribed in clinical practice.3  While randomized control trials (RCTs) have 
shown that both agents reduce the risk of non-vertebral fractures, head-to-head trials 
comparing alendronate and risedronate are underpowered to study fracture outcomes4 
because a large sample size and a long follow-up are required to conduct such a trial.  
Observational studies can present alternative evidence for the relative effectiveness of the 
two drugs.  However, they suffer from unmeasured confounding bias.5  The IV 
approach,6 recently introduced to medical research, is a methodological approach to 
reducing bias due to measured and unmeasured confounding that has been demonstrated 
to provide unbiased estimates of causal effect in observational studies.7  Therefore, it 
presents an opportunity to conduct a head-to-head comparison between alendronate and 
risedronate using observational data and IV analysis. 
The specific aims of this dissertation were as follows.  Aim 1: We proposed a 
new calendar time IV (the date of generic availability) that might be useful for studying 
the comparative effectiveness of prescription drugs.  We presented logical arguments and 
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examined empirical evidence to support the validity of the proposed IV through a study 
of bisphosphonates (alendronate and risedronate).  
Aim 2: We examined the comparative effectiveness of alendronate vs. risedronate 
on the risk of 12 months non-vertebral fractures in women 50 years of age or older using 
the IV proposed in Aim 1. 
Hypothesis: Compared to women initiating risedronate, those initiating 
alendronate had similar rates of 12 months non-vertebral fractures. 
Aim 3: We examined whether two individual IVs can be used to address the same 
question in the same population.  We compared the validity and performance of two IVs, 
the date of generic alendronate availability and the physician preference, in a case study 
of the comparative effectiveness of alendronate vs. risedronate on the risk of non-
vertebral fractures in older women.  
1.2 Background and Significance 
1.2.1 Osteoporosis and Its Public Health Burden 
Osteoporosis is “a skeletal disorder characterized by compromised bone strength 
predisposing a person to an increased risk for fracture”.8  With the aging of the United 
States (U.S.) population, osteoporosis is becoming a common and significant public 
health problem.  First, it is estimated that 44 million Americans, approximately 55 
percent of the population, 50 years and older have osteoporosis and low bone mineral 
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density (BMD).9  Second, Stafford et al. observed a 4-fold increase in physician visits for 
osteoporosis in the U.S. within a decade, from 1.3 million visits in 1994 to 6.3 million 
visits in 2003.1  Third, postmenopausal women are a particularly high risk population for 
this disease, accounting for more than 68% of the people age equal to or greater than 50 
years who have osteoporosis and low BMD in the U.S.9  Finally, despite high prevalence 
of osteoporosis in women, many women either do not receive or chose not to take 
osteoporosis medication.  Yood et al. surveyed 236 women with confirmed diagnosis of 
osteoporosis from one health plan and found that 57.2 percent of them did not initiate 
osteoporosis medications within 3 months of diagnosis.10 
One of the most important complications of osteoporosis is fractures including 
vertebral and non-vertebral fractures.  Chrischilles et al. modeled aspects of lifetime 
osteoporosis impact and found that 54% women age 50 or older will have osteoporosis-
related fractures during the course of their lives.11  The economic burden resulting from 
treating osteoporosis and osteoporosis related fractures has been rising.  Ray et al. 
estimated health care expenditures incurred by osteoporotic fractures in the U.S. in 1995 
were $13.8 billion.12  In 2003, Keen reported that approximate $17 billon has been spent 
annually on the management of osteoporosis in the U.S.13  The costs of treating 
osteoporosis reached more than $19 billion in 2005 and are projected to increase more 
than 48% by 2050.14 
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1.2.2 Treatment of Osteoporosis 
The increasing prevalence of osteoporosis along with the aging U.S. population 
and the substantial economic burden imposed by treating osteoporotic fractures has 
increased the interest in the pharmacologic treatment of osteoporosis.  The Food and 
Drug Administration (FDA) has approved a number of medications for treatment of 
osteoporosis such as alendronate, risedronate, ibandronate, calcitonin, teriparatide, 
zoledronic acid and raxloxifene.15  Hormone therapy has also been used to treat 
osteoporosis.  However, the use of hormone therapy can increase the risk of breast cancer 
and cardiovascular disease in postmenopausal women.16 
Bisphosphonates, including alendronate, risedronate, ibandronate and zoledronic 
acid, are the leading group of medications for treating osteoporosis.1, 2  They decrease 
bone turnover and reduce resorption, which creates a positive bone balance at individual 
remodeling units and continuously improves bone mass.17  Alendronate and risedronate 
are the most commonly prescribed bisphosphonates in clinical practice.3  RCTs have 
consistently shown that compared with a placebo, alendronate and risedronate sustainably 
increase BMD at the spine and hip in a variety of populations including postmenopausal 
women with osteoporosis.18-29  Moreover, high quality evidence from RCTs, and meta-
analyses of RCTs and observational studies have shown that the two bisphosphonates 
prevent vertebral and non-vertebral fractures in women with postmenopausal 
osteoporosis. 4  
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1.2.3 Comparative Effectiveness between Alendronate and Risedronate 
Head-to-head trials have shown that alendronate has a greater effect than 
risedronate on increasing BMD and reducing bone turnover in postmenopausal women.  
In a trial conduced at 78 sites across the U.S., 1,053 women with postmenopausal 
osteoporosis were randomized to alendronate (n=520) and risedronate (n=513).  Rosen et 
al.30 found that patients taking alendronate had greater increases in BMD at hip trochanter 
(alendronate vs. risedronate: 3.4% vs. 2.1%, P<0.001) as well as all other BMD sites at 6 
as well as 24 months from baseline than did patients taking risedronate.  Compared with 
alendronate, risedronate also produced fewer reductions in all studied biochemical 
markers of bone turnover by 3 months.  One year later, Bonnick et al.31 reported the 
results from the first 2 years of the same trial.  They found that compared with patients 
taking risedronate, those receiving alendronate had greater gain in BMD and reduction in 
bone turnover at 24 months.  
While researchers have found strong correlation between BMD or biomarkers of 
bone turnover and fracture,32 there is no conclusive evidence that the difference in BMD 
or in biomarkers of bone turnover can translate into a difference in fracture risk.32-35   
Therefore, evidence on the comparative effectiveness between alendronate and 
risedronate on the risk of non-vertebral fractures is necessary to determine which 
bisphosphonate is more effective in preventing fractures.  However, there has been no 
head-to-head RCT designed to compare the two bisphosphonates on fracture outcomes 
for various reasons such as a substantial financial burden in conducting such a trial.  
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Furthermore, existing head-to-head trials, not designed for investigating the comparative 
effectiveness of the two bisphosphonates on the fracture risk, are either underpowered or 
too short of a duration to detect clinically significant differences in fracture incidences. 4, 
15   
In the absence of head-to-head trials, observational studies provide alternative 
evidence on the relative effects of alendronate, compared to risedronate, on fracture 
outcomes.  We reviewed the literature and found four observational studies comparing 
alendronate and risedronate on non-vertebral fracture incidences.   However, the results 
from the four studies were inconsistent (Table 1-1), although they had similar study 
designs, statistical methods.  Watts et al. 36 analyzed medical and pharmacy claims data 
comparing non-vertebral fractures between new users of alendronate (n=5,024) and 
risedronate (n=1,000) at 6 months, and alendronate (n=3,716) and risedronate (652) at12 
months.  They found a 54% risk reduction for risedronate vs. alendronate (HR =0.46; 
95% CI, 0.02-1.06) at 6 months and a 59% risk reduction for risedronate vs. alendronate 
(HR = 0.41; 95% CI, 0.18 to 0.94) at 24 months.36   Silverman et al. provided similar 
results in an even larger population with12,215 women taking risedronate and 21,615 
taking alendronate.3  They found that women on risedronate had a lower incidence of 
non-vertebral fractures than women on alendronate (HR=0.82; 95%CI: 0.68-0.98) 
through 12 months of therapy.  However, the latest two cohort studies conducted by Cutis 
et al.37 and Cadarette et al.38 showed the difference in non-vertebral fracture risk between 
women on risedronate and alendronate was small and not statistically significant.  For 
example, Cadarette reported a small difference in fractures risk between new recipients of 
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risedronate (n=8,718) and alendronate (n=21,007) with a hazard ratio of 1.07 (95%CI, 
0.85-1.36) at 6 months, 1.01 (95%CI, 0.85-1.27) at 12 months and 0.96 (95%CI, 0.84-
1.11) at 24 months.  
Generally, there is sufficient evidence that both alendronate and risedronate 
increase BMD and reduce bone turnover with alendronate presenting a relatively stronger 
effect.  However, head-to-head trials for the comparative effectiveness between 
alendronate and risedronate on fracture outcomes are lacking.  Observational studies may 
provide an alternative source of evidence, but we found mixed results from observational 
studies given similar study design, statistical analysis and confounder adjustment.  This 
suggests that further research is warranted.  A possible reason for such inconsistent 
results and a potential method to solve such a problem will be discussed in the following 
section.  
1.2.4 A Possible Reason for Inconsistent Results 
Despite using similar observational study designs, statistical analyses and 
confounding adjustment, inconsistent results appeared in the recent studies regarding the 
comparative effectiveness between alendronate and risedronate on the risk of fracture 
outcomes (discussed before). 3, 36-38  One possible explanation for such an inconsistency 
is that observational studies may suffer from confounding bias since participants are not 
randomized to treatment.  Many of the reasons that patients are prescribed a drug are the 
same reasons that determine how well patients do in the outcome (confounding by 
indication).39-42  As a result, evidence obtained from observational studies about the 
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treatment and outcome relationship may be subject to confounding bias.  Methods such as 
conventional regression and propensity score43 analysis have been developed to address 
measureable confounding; however, residual confounding may remain from unmeasured 
factors. 3, 36, 38 
1.3 IV Approach  
1.3.1 Background  
IV analysis, widely used in economics, is one method for addressing both 
measured and unmeasured confounding 44 with observational data.  It is a technique 
enabling researchers to take advantage of observational data such as claims data and 
registry data to more correctly estimate the effectiveness or safety of a medication even if 
unmeasured risk factors are present.  Figure 1-1, adopted from Brookhart et al.,45 
illustrates this technique.46  The central idea of IV analysis is to find a variable that has a 
causal effect with the treatment assignment, in this case a prescription drug, but is not 
related to the outcome, except through its relationship with the treatment assignment.  A 
good IV should satisfy two key assumptions.  First, the IV should be strongly related to 
the treatment assignment.  Second, the instrument should not be correlated with measured 
and unmeasured confounders and only related to the outcome through the treatment 
assignment (exclusion criteria).  This means that the IV should neither be related to risk 
factors of the outcome (the uppermost pathway [dash line] in Figure 1-1) nor have direct 
effect on the outcome (the lowermost pathway [dash-dot line] in Figure 1-1).  Therefore, 
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it is only related with the outcome through the treatment assignment (the middle pathway 
[dot line] in Figure 1-1). 
1.3.2 Examples of Valid IVs 
A special example of a valid IV is the randomization process,47 for example coin 
toss, in a randomized trial for prescription drugs.  It is a strong IV because the treatment 
assignment is solely dependent on the coin toss, which meets the first assumption.  
Second, the likelihood of receiving treatment based on the process, tossing a coin, is 
independent of patient characteristics and it is not related to the outcome, except through 
treatment. This meets another IV assumption.  
IV analysis in observational (i.e. non-randomized) studies attempts to mimic the 
randomization process.  In such an example, Brookhart and colleagues48 were comparing 
Cyclooxygenase 2 (COX-2) inhibitor and non-selective non-steroidal anti-inflammatory 
drugs (NSAID) use and risk of gastrointestinal (GI) complications.  The investigators 
calculated a measure of physician preference for type of drug and used it as an IV.  They 
argued that patients will be more likely to receive a COX-2 inhibitor if their physician 
prefers these agents.  Furthermore, this prescribing preference supersedes an individual 
patient’s indication for this medication, and patients will not select physicians based on 
this prescribing preference.  These arguments suggest that physician’s treatment 
preference may serve as a viable IV.  
11 
 
1.3.3 IV Analysis 
One of the methods of calculating IV estimator for a dichotomous treatment 
assignment and outcome is through two stage least squares (2SLS).44  In general, two 
simultaneous linear equations are built.  The first equation models the probability of 
receiving a treatment assignment given the IV and measured confounders and outputs the 
predicted value.  The second equation models the outcome given the predicted value of 
treatment assignment and measured confounders.  If we consider randomization process 
as an IV, the IV estimator will be the same as results estimated by regression analysis.  
The detailed discussion of IV estimator will be presented in the later sections. 
1.3.4 Application of IV Analysis in Prescription Drug Research 
Research for comparing the safety and effectiveness of prescription drugs may be 
a fruitful area for the application of IV analysis.  This method is gaining popularity in 
prescription drug research.  Comparing the number of published articles from 2001 to 
2003, the number of articles regarding applying IV analysis in prescription drug research 
increased 4-fold from 2004 to 2006 and 8-fold from 2007 to 2009.46  IVs may be derived 
from several levels (regional variation, 49-56 facility prescribing patterns, 57-59 physician 
preference, 60-63  patient history/financial status, 64-66 calendar time 67-70 and others) and 
have been applied in post-market comparative effectiveness research on a variety of  
prescription medications.45, 62, 63  For instance, Brookhart et al.48 calculated a measure of 
physician preference for COX-2 inhibitor over NSAID and used it as an IV in comparing 
the risk of gastrointestinal complications between the two types of medications.  They 
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analyzed the data using both the IV approach and multivariate regression analysis, and 
found that effect estimates from the IV approach were consistent with those from RCTs, 
while results from multivariate analysis were not due to residual confounding from 
unmeasured variables. 
1.4 Research Design and Methods 
1.4.1 Data Source 
This dissertation used the Medstat MarketScan Commercial Claims and 
Encounters (CCE) and Medicare Supplemental Database (Ann Arbor, MI).  Data were 
available for 2005-2009 and partially for 2010.  The MarketScan database captures the 
largest convenient sample of over 73 million unique patients.  Since 1996, it has collected 
information mostly from large employers in the U.S.71  This nationwide database contains 
over 500 million claim records per year from individuals with employer-sponsored health 
insurance.  Information captured in the database includes patient demographics, detailed 
enrollment, inpatient services, physician encounters and pharmacy claims.  Scientific 
studies based on this data source have been reported in more than 100 peer-reviewed 
articles.71 
The MarketScan databases offer advantages over raw administrative claims 
because data files undergo validity and editing procedures to ensure high quality and 
consistency in fields across the years.72  The data are evaluated against population norms, 
previous year summaries, and validated data subsets.  Outliers are flagged and reviewed 
13 
 
for coding or processing errors.  Encounter data are audited at the health plan level, and 
plans submitting incomplete data are excluded.  Diagnostic and procedural codes are 
compared against validity algorithms and set to missing values if inconsistent. 
1.4.2  Organization of the Databases 
The MarketScan databases include fours files: 1) medical and surgical claims, 2) 
aggregated populations table, 3) outpatient pharmaceutical claims table, and 4) annual 
enrollment summary table and enrollment detail table.  The medical and surgical claims 
contain four tables (inpatient admission table, facility header table, inpatient services 
table and outpatient services table).  The inpatient admission table summarizes 
information on hospital admission after identifying all of the encounters or claims 
associated with an admission.  It also includes data such as the principal procedure, 
principal diagnosis, Major Diagnosis Category (MDC), and Diagnosis Related Group 
(DRG).  The inpatient services table records an individual’s facility and professional 
encounters and services through an inpatient admission.  The outpatient services table 
contains information on encounters and claims for services that appear in a doctor’s 
office, hospital outpatient facility or emergency room. The facility header table contains 
complete information on facility claims.  
The aggregated populations table is used to generate quarterly counts of 
individuals with medical, surgical and outpatient pharmaceutical claims in order to 
calculate aggregated rate-based statistics.  The outpatient pharmaceutical claims data are 
available for individuals who have an outpatient dispensing of a medication.  A large 
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portion of the individuals on the medical and surgical claims table can be found on this 
table.  The enrollment tables can be lined to the medical and surgical claims and 
outpatient pharmaceutical table.  They provide individual-level continuous enrollment 
records with demographic information.  
1.4.3 Study Designs and Populations 
Aim 1 
We conducted retrospective cohort studies.  Figure 1-2 shows the sample 
selection strategy.  We selected women, 50 years of age or older, who had ≥1 OP 
diagnosis between 2007 and 2009 (n=729,978).  We further restricted the population to 
women who had continuous enrollment and ≥1 Fracture Risk Assessment Tool (FRAX) 
risk factors73, 74 but no diagnoses of Paget disease (ICD-9-CM code: 731.0) or 
malignancy (ICD-9-CM: 140-208).  We then identified 116,359 women who initiated an 
oral alendronate (10mg or 70mg) or risedronate (5mg or 35mg) or no OP treatment 
within 90 days after the index date (date of the first OP diagnosis).  We excluded women 
who had any OP medications within 12 months before the index date (n=66,564).  The 
final sample included three groups: 1) women initiating an alendronate (n=3,717), 2) 
women initiating a risedronate (n=1,625) and 3) women with no OP treatment 
(n=37,948).  
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Aim 2 and Aim 3 
We conducted a  retrospective cohort study and adopted a new user design75, 76 for 
both studies.  Figure 1-3 shows the sample selection strategy.  We selected women, 50 
years of age or older, who had enrollment information between 2007 and 2009 
(N=8,034,624).  We then identified women who initiated oral alendronate (10mg or 
70mg) or risedronate (5mg or 35mg) during the time period and had continuous 
enrollment before and after the index date ─ date of initiation of an alendronate or 
risedronate (N=360,857).  Individuals were excluded if: 1) they had a bisphosphonate 
within 12 months before the index date (N=249,048); and 2) they had a diagnosis of 
Paget’s disease (ICD-9-CM code: 731.0) or malignant neoplasm (ICD-9-CM: 140-208) 
within one year before the index date (N=11,496).  The study sample for Aim 2 included 
100,313 women, among which 79,370 initiated an alendronate and 32,439 initiated a 
risedronate. Finally, for Aim 3 we restricted our sample to women who had information 
on physician preference.  The analytic sample included 3,190 women, among whom 
2,332 initiated an alendronate and 858 risedronate. 
1.4.4 Measures 
Outcome Variables 
The main outcome variable was an indicator of non-vertebral fractures (including 
hip, wrist/forearm, humerus, clavicle, pelvis, leg fracture).  It was identified during the 
first year (3, 6 and 12 months) following the index date. We used diagnostic and 
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procedure codes from claims to identify non-vertebral fractures based on approaches 
described by previous research 38, 77, 78 (Table 1-2 for ICD codes).  Using claims data to 
identify fracture outcomes will achieve 90% sensitivity if medical records are the 
reference standard.77   
Instrumental Variables  
We used IV analysis with the date of generic alendronate availability (February 1, 
2008) as an IV.  The variable was dichotomized with zero indicating the period before 
February 1, 2008 and one otherwise.  We consider the date of generic alendronate 
availability a valid IV because it satisfies assumptions of a valid IV (detailed discussion 
in Chapter II).  First, the availability of generic alendronate influences medication 
choice.  The use of alendronate increases after its generic version is on the market due to 
drop in price.   Second, the date of generic alendronate availability is not related to 
measured and unmeasured risk factors of non-vertebral fractures. Patient characteristics, 
such as age, frailty and healthy behaviors that may affect their medication choices are 
independent of this date.  
In Aim 3 we also used a physician preference IV that has been applied in several 
studies examining the comparative effectiveness of prescription drugs (i.e. atypical vs. 
typical antipsychotics).45, 61, 63, 79  We adapted a method based on Brookhart et al. to 
measure physician preference - namely the most recent new bisphosphonate prescription 
for a prescriber’s patient other than the present patient.45 
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Covariate Measures 
We measured four domains of variables: demographic characteristics, 
osteoporosis-related variables, co-morbidity and concomitant medications, and health 
services utilization (see Table 1-3 for detail).  Demographic characteristics including age 
were defined at the index.  The rest of the domains of variables were measured during the 
12 months period before the index date.  Osteoporosis related variable included diagnosis 
of osteoporosis.  For co-morbidity, we calculated a co-morbidity risk score from the 
Diagnostic Cost Group Hierarchical Condition Category (DCG/HCC) classification 
system (DxCG, Boston, MA).  The DCG/HCC risk adjuster creates a single score for 
each person based on the presence of 189 medical conditions in the diagnosis fields of 
claims records.  For medications, we first identified specific drugs that may cause OP; 
may treat or prevent osteoporosis and may be associated with fractures (Table 1-3 for 
detailed drug information).  We also measured hospitalization and use of mammogram as 
a proxy for a healthy behavior. 
1.4.5 Statistical Analysis 
Descriptive Statistics (Aim 1, Aim 2, Aim 3) 
We presented means and standard deviations for continuous variables and 
proportions for discrete variables.  We compared means using t-tests and proportions 
using Chi-square tests and Fisher’s exact tests. We examined the distributions of patient 
characteristics by the original treatment (alendronate and risedronate) and then by the two 
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levels of the IV (before and after February, 2008).  The reduction in the imbalance of 
patient characteristics due to the usage of the IV was presented. We also graphed the 
trend of using alendronate before and after it turned generic.  
Conventional Analysis (Aim 2 and Aim 3) 
We examined the crude association between study bisphosphonates and non-
vertebral fracture outcomes using simple linear regressions.  We also conducted multiple 
linear regressions to assess the association adjusting for variables described in the 
covariates section.  We reported risk differences (RDs) from the linear regressions.  The 
reason we chose linear regression instead of logistic regression was that linear reports RD 
which can be used to compare results between the conventional analyses and the IV 
analyses.48  
Two Stage Least Squares (Aim 2 and Aim 3) 
We also examined the association between study bisphosphonates and non-
vertebral fracture outcome using an IV analysis.  The 2SLS has been used in the IV 
analysis with a binary treatment assignment and outcome by many researchers.  It 
involved two simultaneous multiple linear regression models.  In general, in the first 
stage, we regressed the treatment assignment on the IV and other measured confounders.  
In the second stage, we regressed the outcome on the predicted values of treatment 
assignment obtained from the first stage and other measured confounders. 
First Stage Model 
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The first stage model is specified as 
Equation (1) 
E[Ti |IVi, Xi] =Pr (Ti=1| IVi , Xi) = α0+α1IVi+ αjXji
m
j=2  
where E[T|IV] indicates the expected value of the treatment assignment for the ith patient 
given the IV after controlling for measured covariates. T equals to 1 when the patient 
receives an alendronate and 0 otherwise.  IV is the date of generic alendronate 
availability.  It equals to 1 when the date is after February, 2008 and 0 otherwise.  X is a 
vector of measured covariates. α1 estimates the increase in the probability of receiving an 
alendronate after the date of generic alendronate availability. 
Second Stage Model 
The second stage predicts the probability of the outcome given the probability of 
receiving an alendronate estimated from the first stage. The model is specified in 
equation 2. 
Equation (2) 
E[Yi|IVi, X i]=Pr (Yi=1| Pr (Ti=1| IV i , Xi), Xi) = β0+β1 Pr (Ti=1| IV i , Xi) + 
 β
j
Xji
m
j=2
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Equation (3) 
IV estimator = β
1
 = 
Pr  Yi = 1 Pr  Ti = 1 IVi = 1, Xi), Xi) − Pr (Yi = 1| Pr  Ti = 1 IVi = 0, Xi), Xi)
Pr  Ti = 1 IVi = 1, Xi) − Pr (Ti = 1| IVi = 0, Xi)
 
Equation (4) 
IV estimator = 
 
E[Y|IV = 1] − E[Y|IV = 0]
E[T|IV = 1] − E[T|IV = 0]
 
In the equation (2), Y represents the outcome, an indicator of non-vertebral 
fracture.  It equals to 1 when a patient has at least one non-vertebral fracture and 0 
otherwise.  𝛽1 (Equation (3)) is the IV estimator for equation (2).  Equation (4) is the 
simplified version of equation (3) and it represents the difference in the outcome given 
the IV divided by the difference in the treatment probability given the IV.  It estimates 
the adjusted risk difference in probability of the outcome between the two hypothetical 
cases, predicted by the IV.  Therefore, it represents the causal effect of the treatment on 
the outcome.  When the IV perfectly predicts the treatment assignment, the IV estimator 
is equal to the risk difference in the outcome between the two medications. 
Performance of IVs and Compare Two IVs (Aim 1 and Aim 3) 
In Aim 1 we examined the performance of the proposed IV (detailed discussion in 
Chapter II) and in Aim 3 we compared the performance of the two IVs (detailed 
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discussion in Chapter IV) based on empirical evidence of the assumptions of a valid IV.  
First, we examined the strength of the IV by reporting F statistics from the first stage of 
the 2SLS.  F statistic ≥ 10 indicates a strong IV80 and a greater F statistic indicates a 
stronger IV.  Second, we assessed the ability of IVs to balance measured patient 
characteristics.  A stronger IV should be associated with fewer measured confounders.81   
We also assessed the balance of patient characteristics by reporting standardized 
differences between the original treatment and between the two levels of the IV.  The 
standardized difference is specified in equation (5) and (6) for means and proportions.82  
In equation (5), d represents the standardized difference; Xtreatment1 and Xtreatment2 are the 
sample mean of the covariate in treatment 1 and treatment 2 respectively and S2treatment1 
and S2treatment2 are the sample variance of the covariate in treatment 1 and treatment 2 
respectively.  In equation (6), d represents the standardized difference and Ptreatment1 and 
Ptreatment2 are the sample proportion of the covariate in treatment 1 and treatment 2 
respectively.  
Equation (5) 
𝑑 =  
(𝑥𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 1 − 𝑥𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 2)
 𝑠
2
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 1 − 𝑠2𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 2
2
 
Equation (6) 
𝑑 =  
(𝑝 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 1 − 𝑝 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 2)
 𝑝 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 1(1 − 𝑝 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 1) − 𝑝 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 2(1 − 𝑝 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 2)
2
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Finally, the assumption that a valid IV should not directly cause a patient outcome 
is not verifiable.  We adopted a method by Newhouse and McClellan6 to indirectly verify 
this assumption.  We assessed whether the IVs were able to keep balance of the 
distribution of the short-term outcomes (i.e. 3-month non-vertebral fracture) that cannot 
be affected by the medical intervention (bisphosphonates). 
1.5 Summary and Innovations 
In summary, osteoporosis is a significant public health problem in the U.S.  It not 
only affects the physical well-being of the older women but also creates a substantial 
financial burden for the health care system.  Effective pharmacologic treatment for 
osteoporosis will help improve the health of women with osteoporosis as well as prevent 
or attenuate future costly procedures associated with osteoporotic fractures in this 
population.  The mainstay of osteoporosis medications are bisphosphonates of which 
alendronate and risedronate are the most commonly prescribed in clinical practice.  
However, there has been no head-to-head trial evaluating the effects of these two 
bisphosphonates on fracture outcomes. 
In the absence of RCTs, observational studies are necessary to provide alternative 
evidence on the comparative effectiveness between alendronate and risedronate on 
fracture outcomes.  However, existing observational studies have provided inconclusive 
results partially due to residual confounding from unobserved variables such as patients’ 
health status or behavior.  IV analysis may be one method to address unmeasured 
confounding bias in observational studies.  While it has not been applied in 
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bisphosphonate research, it has been used in research on a variety of other prescription 
medications.  
In this dissertation, we applied the IV approach with an IV, date of generic 
alendronate availability, to evaluate the comparative effectiveness between alendronate 
and risedronate using observational data.  This dissertation improved current research in 
several ways.  First, we extended the IV approach to research on bisphosphonates.  
Second, compared with the current observational studies on bisphosphonates, this 
dissertation may more accurately estimate the relative effects between alendronate and 
risedronate because IV analysis is not subject to unmeasured confounding bias.  Third, 
the study results extended the current evidence of the comparative effectiveness between 
the two most commonly prescribed bisphosphonates.  Finally, we proposed and provided 
empirical evidence of a new IV that might be used for future prescription drug research. 
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Table 1-1: Estimates of the Comparative Effectiveness of Alendronate vs. Risedronate on the Risk of Non-vertebral 
Fractures from Four Existing Observational Studies 
Authors and 
publication year 
Population Methods Adjusted variables Adjusted HR and 95% 
CI (Risedronate vs. 
alendronate) 
Watt et. al. 200436 6 mo: 
Alendronate 
(n=5,307) 
Risedronate 
(n=1,000) 
 
12 mo:  
Alendronate 
(n=3,716) 
Risedronate  
(n=652) 
Cox-
proportion 
regression 
Age, sex hormone therapy use, prior 
fragility fracture and number of 
concomitant medications in the 
pretreatment period 
6 mo:   0.46 (0.2-1.06) 
12 mo: 0.41 (0.18-0.94) 
Silverman et. al. 
20073 
Alendronate 
(n=21,615) 
Risedronate 
(n=12,215) 
Cox-
proportion 
regression 
Age, estrogen use, number of 
medications, rheumatoid arthritis, history 
of non-vertebral fractures 
6 mo:   0.81 (0.65-1.00) 
12 mo: 0.82 (0.68-0.98) 
Curtis et. al. 200937 Alendronate 
(n=12,956) 
Risedronate 
(n=6,107) 
Cox-
proportion 
regression 
Age, number of outpatient visits, 
Charlson co-morbidity index, use of 
screening tests including BMD, prior 
fracture, and use of prior estrogen, 
glucocorticoids and non-bisphosphonate 
osteoporosis medications 
12 mo: 1.12 (0.70-1.79) 
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Cadarette et. al. 
200938 
Alendronate 
(n=21,007) 
Risedronate 
(n=8,718) 
Cox-
proportion 
regression 
Propensity score + age, race, diagnosis 
of osteoporosis, previous vertebral 
fracture, and previous non-vertebral 
fracture, stratified by state 
6 mo:   1.07 (0.85-1.36) 
12 mo: 1.01 (0.85-1.21) 
24 mo: 0.96 (0.84-1.11) 
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Table 1-2: Codes for Non-vertebral Fractures 
Fracture 
site 
ICD-9 ICD-9 
procedures 
CPT 
Wrist 813.x, 
813.4x, 
813.5x,  
79.02, 
79.12, 
79.22, 
79.32 25600, 25605, 25611, 25620 
Hip 820.x, 
821.x 
79.x5, 
79.05, 
79.15, 
79.25, 
79.35,  27230-27248 
Humerus 812.20, 
812.21, 
812.30, 
812.31,  
78.12, 
78.52, 
79.11, 
79.21, 
79.31 24500, 24505, 24515, 24516 
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Table 1-3: Variable Definition and Coding 
Variable Definition Coding 
Demographics   
   Age Age at the time of the 
index date 
Will be categorized 
Osteoporosis related measures   
   Osteoporosis diagnosis ICD-9 code 733.0x Dichotomous 
Non-vertebral Fractures history See table 1 Dichotomous 
Co-morbidity conditions DCG/HCC Original score or quartiles 
Drugs that cause OP   
   Glucocorticoid Any pharmacy claim Dichotomous 
   PPI Any pharmacy claim Dichotomous 
   H2 Inhibitor Any pharmacy claim Dichotomous 
   Thyroid drug  Any pharmacy claim Dichotomous 
Drugs that treat/prevent OP   
   Vitamin D Any pharmacy claim Dichotomous 
   Estrogen Any pharmacy claim Dichotomous 
   SERMs Any pharmacy claim Dichotomous 
   Parathyroid Hormone Any pharmacy claim Dichotomous 
   Calcitonin   
Drugs associated with fracture   
    Benzodiazepine Any pharmacy claim Dichotomous 
    SSRI/Non-SSRI Any pharmacy claim Dichotomous 
    Anticonvulsant Any pharmacy claim Dichotomous 
    Hypnotics Any pharmacy claim Dichotomous 
    B blocker Any pharmacy claim Dichotomous 
    Thiazide Any pharmacy claim Dichotomous 
    NSAIDS/Cox-2 inhibitor Any pharmacy claim Dichotomous 
Geography   
    North Central   
    Northeast   
    South   
    West   
Health plan type   
    Comprehensive   
    HMO   
    POS   
    PPO   
Health service utilization   
    Hospitalization Hospital claim Dichotomous 
    Mammogram CPT code Dichotomous 
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OP= osteoporosis; DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  
SSRI=selective serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory 
drug;  Cox-2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of 
Service; PPO=Preferred Provider Organization 
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IV 
Risk factors 
 
Treatment Outcome 
Figure 1-1: Instrumental Variable Approach 
Uppermost pathway: IV is not related with risk factors of the outcome  
Lowermost pathway: there is no direct effect on the outcome  
Adopted from Brookhart et. al.  
The two parallel lines means no association. 
Middle pathway: IV is only correlated with the outcome through treatment assignment. 
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Figure 1-2: Sample Selection Strategy for Aim 1* 
Women, ≥ 50 years old, who had ≥ 1 
diagnosis of OP in outpatient or inpatient 
claims between 2007 and 2009 (729,978) 
Index date: date of the first OP diagnosis 
 
Total population (~ 5 million each year) 
Women who had at least one FRAX factor 
but no diagnoses of Paget disease or 
malignancy within a year before the index 
date (N=128,859) 
Women who initiated a study 
bisphosphonate or no-OP treatment within 
90 days after the index date (N=116,359).  
Ale= 5,708, Ris= 2742, None= 101,404; 
Women without any OP treatment before 
the index date (N=43,290). 
Ale= 3,717, Ris= 1,625, None= 37,948 
1. Women without 1-year continuous 
enrollment before and after the index date 
2. Women without any FRAX factors 
within a year before the index date  
3. Women without diagnosis of Paget’s 
disease and Malignancy  
(N=601,119) 
Women who initiated an OP drug other 
than the study drugs (N=19,005) 
Women with any OP drugs other than the 
study drugs within 12 months before the 
index date (N=66,564) 
* OP: osteoporosis, FRAX: Fracture Risk Assessment Tool , Ale: Alendronate, Ris: Risedronate 
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Women, ≥ 50 yrs, who had enrollment 
information between 2007 and 2009 
(N=8,034,624) 
Women with 1 year continuous enrollment 
before and after initiation of an alendronate 
or risedronate (N=360,857):  
Aln (n=255,612); Ris (n=105,245) 
 
Women who  
1) did not initiate an alendronate or 
risedronate  
or  
2) did not have two years continuous 
enrollment before and after the 
index date if they initiated an 
alendronate or risedronate 
 
(N=7,673,767) 
 
Women who had any bisphosphonates 
within one year before the index date 
(N=249,048) 
Aln (n=176,242), Ris (n=72,806) 
 
Women who were new alendronate or 
risedronate users (N=111,809) 
Aln (N=79,370), Ris (N=32,439) 
 
    
 
 
Study sample (N=100,313) 
Aln=71,034; Ris=29,279 
 
    
Women who had Paget’s disease or 
malignancy within a year before the index 
date (N=11,496).  
 
Study sample (N=3,190) 
Aln = 2,332; Ris = 858 
 
    
Women without information on physician 
preference 
 
    
*Aln=Alendronate, Ris =Risedronate 
Figure 1-3: Sample Selection Strategy for Aim 2 and 3* 
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2 CHAPTER II: DATE OF GENERIC AVAILABILITY - A 
POTENTIAL INSTRUMENTAL VARIABLE IN THE 
COMPARATIVE EFFECTIVENESS RESEARCH OF 
PRESCRIPTION DRUGS 
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2.1 Introduction 
Observational studies using large administrative data can provide essential 
evidence for the comparative effectiveness of prescription drugs.83  However, 
observational studies may produce biased results due to unmeasured confounding84 (e.g. 
administrative data do not generally have information on important factors such as 
healthy behaviors and frailty).  The instrumental variables (IV) approach has been 
proposed as one way to address both measured and unmeasured confounding.6  The main 
challenge is finding a credible IV47 that is: 1) highly associated with the treatment choice 
and 2) independent of measured and unmeasured confounders, and has no direct effect on 
the outcome (two assumptions).81, 85  
In this paper, we provide the theoretical foundation and empirical evidence for a 
new IV that may be useful in comparative effectiveness studies of prescription drugs---
namely, the date that generic products become available.  In general, the patent expiration 
of the brand name medication is followed by the availability of generic versions that are 
substantially less costly and may increase treatment use.  This natural variation in 
treatment choice may provide a valid IV.  We also tested  the validity of this IV using the 
patent expiration of the bisphosphonate alendronate (brand name Fosamax) and two 
comparison groups: 1) individuals not taking any osteoporosis (OP) treatment, and 2) 
individuals taking an alternative bisphosphonate risedronate (brand name Actonel), which 
is still under patent protection.  The reasons for selecting these comparisons are: 1) 
alendronate is an example of a popular “blockbuster” drug that became available as 
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generic in February 2008, 2) the no OP treatment group provides an opportunity to 
explore the performance of the IV under the scenario of a “placebo” control; 3) the 
risedronate treatment group provides allows us to assess the performance of the IV under 
a comparative effectiveness scenario.  Finally, we discuss the potential implications of 
this IV in prescription drug research. 
2.1.1 Theoretical Foundation of the Proposed IV 
The validity of an IV depends on its ability to satisfy the two restricted 
assumptions.  It is unnecessary to conduct the IV analysis if we do not have a strong 
theoretical foundation to support the validity of the proposed IV.81 
We posit that the date of generic availability satisfies the first IV assumption, 
namely that the IV is highly associated with the treatment choice, according to the 
following rationale.  After a brand name medication loses its patent protection, the use of 
the generic equivalents can occur quickly and the effect can be large.  Empirical evidence 
supporting this statement comes from two sources. First, the Hatch-Waxman Act allows 
generic manufacturers to initiate clinical tests for the generic product before expiration of 
the patent.86  This speeds up the entry of generics to within several months after the 
original drug’s patent expiration.86  Empirical studies have shown that the generic share 
of all prescriptions has been rising steadily in the last few decades:  from 19% in 1984 to 
75% of all prescription drugs by 2009 87.  This growth in generic utilization may be due 
to 1) increase in generic availability of popular “blockbuster” drugs – drugs with annual 
sales exceeding $1 billion, such as Zocor (simvastatin) and Plavix (clopidogrel) which 
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expired in 2006; Ambien (zolpidem), Norvasc (amlodipine) and Protonix (pantoprazole) 
2007; Fosamax (alendronate) 2008 and Prevacid (lansoprazole) 2009 87; and 2) expansion 
in drug coverage for generic products and lower co-pay incentives for generic 
utilization87. 
Second, increases in the use of a brand name drug and its generic equivalents can 
also come from reductions in use of other brand name drugs indicated for the same 
medical conditions.  Berndt and Aitken studied intermolecular substitution following the 
loss of patent protection of Zocor (simvastatin), a brand name  cholesterol-lowering 
statin.87  They argued that sales of a medication (brand plus generics) might increase 
following patent expiration whereas other patent protected branded drugs treating the 
same medical condition might fall.  In 2007, a year after the generic availability of Zocor 
(simvastatin), Lipitor was still under patent protection.  Total monthly Zocor and its 
generic simvastatin prescriptions increased from 2.6 million in 2006 to 4.8 million by the 
end of 2007.  In contrast, sale of Lipitor fell 12% in the same period.  They found that the 
increase in total dispensing of Zocor and generic simvastatin came from two sources: 1) 
patients switched from Lipitor and 2) patients initiated Zocor or its generic simvastatin. 
We also argue that the date of generic availability satisfies the second IV 
assumption of no direct or indirect association with the patient outcome except through 
treatment assignment. The date of generic availability is a calendar time IV so any 
residual confounding can only occur by factors that vary at the exact same time as the IV.  
For instance, changes in insurance status must vary at the same time as the study 
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medication goes off patent or, any changes in healthy behaviors must coincide with the 
date of generic availability.  Similarly, the date of generic availability is unlikely to have 
direct effect on patient outcomes (i.e. fracture).  Furthermore, seasonal trends may impact 
patient outcomes such as the mortality and fracture rate; however, they can be accounted 
for in the statistical model and by including enough data for the pre and post period of the 
generic availability.  
2.1.2 Rationale for Testing for the Validity of the IV 
In the demonstration studies, we will test for the validity of the IV wherever 
possible. For the first assumption, it is shown in the literature that a strong IV should 
explain variation of the treatment choice.6  If we regress the treatment assignment on the 
IV and measured covariates, a strong IV should yield a partial F statistic greater than or 
equal to 10.80  However, in theory the second assumption is not verifiable.  Researchers 
have suggested several indirect methods to support this assumption.  For instance, 
Brookhart et al. have shown that a valid IV should reduce the imbalance of patient 
characteristics by the original treatment assignment.81  Furthermore, Newhouse and 
McClellan have shown that a valid IV (differential distance) should be able to restore 
balance in short-term outcomes (i.e. one-day mortality) that cannot be affected by the 
medical intervention (catheterization).6  
In the case of the bisphosphonates, alendronate and risedronate have a delayed 
mechanism of action, which can be used for assessing the validity of the IV.  These 
agents cannot impact short-term non-vertebral fracture rates (i.e. within 3 months of 
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initiation) so a valid IV should be able to impose balance on 3-month non-vertebral 
fracture rates that may be imbalance according to the actual treatment assignment.  
2.2 Methods 
2.2.1 Data Source 
This study used the Medstat MarketScan Commercial Claims and Encounters 
(CCE) and Medicare Supplemental Database (Ann Arbor, MI).  Data were available for 
2005-2009 and partially for 2010.  The MarketScan database captures the largest 
convenient sample of over 73 million unique patients.  Since 1996, it has collected 
information mostly from large employers in the U.S.71  This nationwide database contains 
over 500 million claim records per year from individuals with employer-sponsored health 
insurance.  Information captured in the database includes patient demographics, detailed 
enrollment, inpatient services, physician encounters and pharmacy claims.  Scientific 
studies based on this data source have been reported in more than 100 peer-reviewed 
articles.71 
2.2.2 Study Design and Population 
We conducted retrospective studies.  Figure 2-1 shows the sample selection 
strategy.  We selected women, 50 years of age or older, who had ≥1 OP diagnosis 
between 2007 and 2009 (n=729,978).  We further restricted the population to women 
who had continuous enrollment and ≥1 FRAX risk factors73 but no diagnoses of Paget 
disease (ICD-9-CM code: 731.0) or malignancy (ICD-9-CM: 140-208) (n=128,859).  We 
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then identified 116,359 women who initiated oral alendronate (10mg or 70mg) or 
risedronate (5mg or 35mg) or no OP treatment within 90 days after the index date (date 
of the first OP diagnosis).  We excluded women who had any OP medications within 12 
months before the index date (n=66,564).  The final sample includes three groups: 1) 
women initiating an alendronate (n=3,717), 2) women initiating a risedronate (n=1,625) 
and 3) women with no OP treatment (n=37,948).  
2.2.3 Measures 
Outcome 
The main outcome variable was an indicator of non-vertebral fracture (including 
hip, wrist/forearm and proximal humerus) at three months.  It was identified during the 
first 3 months following the index date.  We used diagnostic and procedure codes from 
claims to identify non-vertebral fractures based on approaches described by previous 
research.38, 78 
Main Exploratory Variable 
The main exploratory variable was an indicator of alendronate or risedronate.  We 
identified alendronate or risedronate using national drug code (NDC). 
Patient Characteristics 
We determined patient demographic characteristics at the index date and other 
characteristics using claims from inpatient services, outpatient services and pharmacy 
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claims within 12 months before the index date.  The characteristics included: 1) patient 
demographic (age); 2) history of non-vertebral fracture and diagnosis of osteoporosis; 3) 
co-morbidity measured by the Diagnostic Cost Group Hierarchical Condition Category 
(DCG/HCC) classification system (DxCG, Boston, MA);88 4) co-medications (drugs that 
may cause osteoporosis, treat/prevent osteoporosis and drugs associated with fracture); 5) 
health services utilization (hospitalization and screening mammogram); 6) geographic 
location of primary beneficiary’s residence; and 7) types of health plans.  
We measured patient’s age in years.  For patient history, a diagnosis of 
osteoporosis was defined as having a diagnostic code of 733.0x.38  We defined history of 
non-vertebral fracture as having a diagnosis of hip fracture, wrist/forearm or proximal 
humerus within a year prior to the index date.  We measured co-morbid condition using 
the DCG/HCC classification system.  The DCG/HCC risk adjuster creates a single score 
for each person based on the presence of 189 medical conditions in the diagnosis fields of 
claims records.  Despite its development for Medicare billing purpose, the DCG/HCC has 
been widely applied as a measure of confounding in studies of drug use.89  We grouped 
concomitant medications based on their relationships with osteoporosis and fracture. 
Drugs that may cause osteoporosis included glucocorticoids,90 H2 inhibitors, proton 
pump inhibitors (PPI)91 and thyroid medications.92  Drugs that treat or prevent 
osteoporosis included calcitonin, vitamin D, estrogen, selective estrogen receptor 
modulator (SERM) and parathyroid hormone.15  Drugs that may be associated with 
fracture included psychotropic medications (benzodiazepine, selective serotonin reuptake 
inhibitor [SSRI], non-SSRI antipsychotic, anticonvulsant and hypnotics),93 cardiovascular 
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medications (beta blocker and thiazide),94, 95 and anti-inflammatory drugs (non-steroidal 
anti-inflammatory drug [NSAID] and cyclooxygenase 2 [COX2] inhibitor).  Health 
services utilization variables included any hospitalization and any screening mammogram 
as proxy for health behavior.  We categorized geographic location of primary 
beneficiary’s residence into north central, northeast, south and west.  Types of health 
plans included comprehensive plan, health maintenance organization (HMO), point of 
service (POS), and preferred provider organization (PPO).   
Instrumental Variable 
The instrumental variable, the date of generic alendronate availability, was 
defined as February 2008.  We set it to 1 if after February 2008 and 0 otherwise. 
2.2.4 Statistical Analysis 
We performed the same analyses for comparing alendronate with no OP treatment 
and comparing alendronate with risedronate.  We described analyses for one comparison 
(alendronate vs. risedronate) as an example.  Our analyses emphasized on examining the 
two assumptions of a valid IV. 
We described patient characteristics stratified by the two treatment groups 
(alendronate vs. risedronate) and by the two levels of the IV (before and after February 1, 
2008).   For the first assumption, we graphed the trend of the use of alendronate as 
compared with risedronate in the study sample over time.  To examine the strength of the 
IV, we conducted a multivariate linear regression.  We regressed the treat assignment on 
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the IV and other measured covariates including demographics, osteoporosis related 
factors, co-morbidity, medications, health services utilizations, region of residence and 
health plan types.  We reported partial F statistic and partial R square for the IV.  
We examined the second assumption based on approaches suggested by 
Brookhart et al and Newhouse and McClellan.6, 81  We calculated standardized 
differences82, 96 in patient characteristics between the two treatment groups and between 
the two levels of the IV to assess balance across measured confounders.  A valid IV 
should have smaller standardized differences.  
Furthermore, we calculated standardized difference in the 3-month non-vertebral 
fracture between the two treatment groups and the two levels of the IV.  A valid IV 
should provide more balance of the 3-month non-vertebral fracture than the treatment 
assignment. 
All analyses were conducted using STATA 10.0 (Stata Corp 2007, College 
Station, TX).  The study received an exemption from the Institutional Review Board of 
University of Massachusetts Medical School.  
2.3 Results 
We identified a study cohort of 43,290 women.  Among them 3,717 initiated an 
alendronate, 1,625 initiated a risedronate and 37,948 initiated no OP treatment (Figure 2-
1).  Table 2-1 shows the characteristics of the cohort.  The average age of the cohort was 
approximately 65 years.  The mean co-morbidity score (DCG/HCC) was 0.86.  Most 
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patients had comprehensive insurance or PPO and were located in the north central and 
the south. 
Figure 2-2 provides information about the association between the IV and 
treatment assignment, when the comparator is no OP treatment.  This figure shows that in 
the year before the availability of generic alendronate, only 10% of women who were at 
risk for osteoporotic fractures initiated alendronate therapy.  After generic availability, 
this rate did not change.  We conclude from this graph that the IV may not be strongly 
associated with the treatment choice (alendronate vs. no OP treatment). 
Figure 2-3 illustrates the association between the IV and treatment assignment, 
when the comparator is risedronate.  This figure shows that approximately 60% of 
women who were at risk for osteoporotic fractures initiated an alendronate in the year 
before the availability of generic alendronate.  In contrast, this rate increased after generic 
alendronate availability with 92% of the women initiating an alendronate by the first 
quarter of 2009.  We conclude from this graph that the IV may be strongly associated 
with the treatment choice (alendronate vs. risedronate). 
Table 2-2 shows the strength of the IV in inducing variation of the treatment 
choice, as part of testing the first assumption.  In the comparison of alendronate vs. no 
OP treatment, we found that IV explained only a modest amount of variation of the 
treatment assignment, although it was statistically significant.  The partial F statistic was 
5.24 and partial R square was 0.0001.  In comparison, the IV explained more of the 
variation of treatment choice between receiving alendronate vs. risedronate (partial F 
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statistic = 301.99 and partial R square = 0.0538), and this was also statistically 
significant.  We conclude from this table that the IV is a weak IV in the comparison of 
alendronate vs. no OP treatment while a strong one in the comparison of alendronate vs. 
risedronate. 
Tables 2-3 and 2-4 demonstrate the ability of the IV to impose balance across 
measured characteristics of the study populations.  Table 2-3 shows the distribution of 
patient characteristics between women who initiated an alendronate and those with no OP 
treatment with and without the IV.  Without the IV, we found that the two groups were 
quite different across most characteristics, and a simple comparison of treatment effects 
would be highly susceptible to bias.  With the IV, we found that patient characteristics 
became more balanced before and after February 2008.  For instance, compared to 
women without OP treatment, those who initiated an alendronate were older (mean age: 
67 vs. 65), had a greater co-morbidity score (median DCG/HCC score 0.67 vs. 0.64) and 
had a higher history of osteoporotic fracture (7.65% vs. 11.43%).  Women without OP 
treatment also had more medications and utilized more health services as compared to 
those with alendronate.  Resorting the groups by the IV resulted in more balance of these 
characteristics, as evidence by the reductions in the standard differences.  A reduction in 
imbalance can also be found in the history of non-vertebral fracture, one of the strongest 
predictors for fracture.  We found 7.80% of women had a history of non-vertebral 
fracture before February 2008 and 8.20% after.  In contrast, the proration with a history 
of non-vertebral fracture was lower in the group without OP treatment compared to the 
group with alendronate (11.43% vs. 7.65%). 
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Table 2-4 shows the distribution of patient characteristics between women who 
initiated an alendronate and who initiated a risedronate with and without the IV.  We 
found that women with alendronate and those with risedronate were similar in 
characteristics with and without the IV.  For instances, compared to patients initiating 
risedronate, those initiating alendronate were relatively younger (mean age: 67.20 vs. 
67.30); had a higher proportion of fracture history (11.43% vs. 10.46); and had a lower 
co-morbidity score (median DCG/HCC score: 0.67 vs. 0.70).  The medication utilizations 
were similar between the two groups.  More women initiating a risedronate had a 
comprehensive health plan while more women initiating an alendronate had an HMO.  
For health services utilization, alendronate initiators had fewer hospitalizations (20.80% 
vs. 21.48%) and more screening mammograms (36.83% vs. 35.26 %).  Resorting the 
groups by the IV did not result in more balance of these characteristics.  The standardized 
differences in patient characteristics were even larger between the two levels of the IV 
than between treatment groups.  We conclude from Table 2-3 and 2-4 that the IV may 
provide better balance of patient characteristics in the comparison of alendronate vs. no 
OP treatment than in the comparison of alendronate vs. risedronate. 
Table 2-5 also shows the indirect evidence for the validity of the IV according to 
the second assumption.  This table shows the balance of the short term outcome, non-
vertebral fracture at 3 months, with and without the IV.  In the comparison of alendronate 
vs. no OP treatment, we found a 0.08% difference in the non-vertebral fracture at 3 
months between the treatment and the control (alendronate vs. no OP treatment: 0.79% 
vs. 0.88%).  Resorting the groups by the IV resulted in balance of the 3-month outcome 
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(before vs. after, February, 2008: 0.88% vs. 0.86%).  The standard difference of the 
outcome was smaller with the IV than without the IV (IV vs. No IV: 0.06% vs. 0.24%).  
In the comparison of alendronate vs. risedronate, we found a 0.17% difference in the 3-
month non-vertebral fracture (alendronate vs. risedronate: 0.79% vs. 0.96%).  Resorting 
the groups by the IV provided more balance of the 3-month outcome (before vs. after, 
February, 2008: 0.83% vs. 0.86%).  The standard difference of the outcome was smaller 
with the IV than without the IV (IV vs. no IV: 0.08% vs. 0.53%).  We conclude from this 
table that the IV imposed more balance on 3-month non-vertebral fractures than the 
original treatment assignment.  
2.4 Discussion 
In this paper we introduced a new IV, the date of generic availability, and 
demonstrated how this IV performed when used to study treatment effectiveness with a 
“placebo” control and with an active control.   
We reasoned that the date of generic availability would be associated with patient 
treatment choice (the first IV assumption) due to the lower price of the generic 
equivalent.  We found empirical evidence supporting this argument in the literature. 
Furthermore, in our demonstration study, we found that the use of Fosamax and generic 
alendronate as compared with Actonel (risedronate) increased after the availability of 
generic alendronate, from approximately 60% among all women initiating an alendronate 
or risedronate in 2007 to approximately 90% in 2009.  However, we did not find that 
overall use of alendronate increased among all women at risk for osteoporotic fractures.   
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This suggests that the IV may not be strongly associated with the treatment choice when 
the comparator is a “placebo” control. 
In order to be a valid IV, the date of generic availability must also demonstrate the 
ability to balance measured and unmeasured confounders while not directly causing the 
outcome (the second IV assumption).  This is not a directly verifiable assumption; 
however, we did provide both logical arguments and indirect empirical data to support 
this assumption.   We further demonstrated that the IV could impose adequate balance of 
patient characteristics in comparisons of alendronate vs. no OP treatment and alendronate 
vs. risedronate although there was some residual imbalance in the comparison of 
alendronate vs. risedronate.  Finally, we showed that the IV did not directly cause the 
outcome because the IV was not associated with the 3 month non-vertebral fracture. 
Comparing with the original treatment assignment, the IV provided more balance of the 3 
month non-vertebral fracture.  Therefore, the proposed IV satisfies the second 
assumption.  
While we demonstrated the date of generic availability may be a valid IV for 
some comparative effectiveness studies it has limitations.  First, this IV cannot be used in 
comparing two patent protected drugs.  Second, the strength of this IV requires further 
examination, especially with other prescription drugs.  Our own examination revealed 
that the IV appeared to be weak when the comparator was a “placebo” control (no OP 
treatment).  A possible reason is that the prescribing pattern of OP treatment may not 
change because of the generic availability of alendronate.  Without a strong variation in 
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the use of alendronate overtime, the first assumption of a valid IV is violated.  In contrast, 
when we compared alendronate with risedronate, we found an increasing trend of using 
alendronate among women who initiated a study bisphosphonate (from 60% in 2007 to 
90% in 2009).  The high partial F statistic (F statistic = 301.99> 10) also supported this 
argument.  This suggested that the date of generic alendronate availability did induce the 
variation in the use of alendronate among bisphosphonate users.  A possible reason for 
this observation is that once a woman was prescribed a bisphosphonate treatment, she 
was more likely to receive an alendronate than a risedronate after generic alendronate 
availability.  
Third, it appears that the IV, the date of generic availability, may perform best 
when there is strong evidence of confounding by indication; we can show that the IV not 
only balances observed patient characteristics but reduces the imbalance of these 
characteristics by original treatment groups.  Moreover, it is unnecessary to apply the IV 
analysis without strong evidence of confounding by indication.81  In our study comparing 
alendronate with no OP treatment, we expected a strong confounding by indication.  
Compared to women initiating an alendronate, women without OP treatment were 
younger, had less co-morbidity and history of fracture, and may have had healthier 
behaviors (unobserved).  Whether a woman will receive an alendronate or no OP 
treatment may depend on these measured and unmeasured characteristics that are 
correlated with the outcome (non-vertebral fracture).  We found that the IV could balance 
the observed patient characteristics which implied that it might also balance unmeasured 
characteristics.  In contrast, in our example comparing alendronate with risedronate, we 
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did not find a reduced imbalance by the proposed IV because there was not strong 
evidence of confounding by indication.  
Our study suggests that the date of generic availability may be a useful IV for 
studying the comparative effectiveness of prescription drugs.  We also acknowledge that 
the proposed IV has limitations.  Future research should evaluate whether the IV could 
induce the variation of treatment choice and examine the confounding by indication 
before applying this IV.  Additionally further studies are warranted to provide evidence 
of the validity of the proposed IV in a variety of therapeutic areas. 
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Figure 2-1: Sample Selection Strategy 
Women, ≥ 50 years old, who had ≥ 1 
diagnosis of OP in outpatient or inpatient 
claims between 2007 and 2009 (729,978) 
Index date: date of the first OP diagnosis 
 
Total population (~ 5 million each year) 
Women who had at least one FRAX factor 
but no diagnoses of Paget disease or 
malignancy within a year before the index 
date (N=128,859) 
Women who initiated a study 
bisphosphonate or no-OP treatment within 
90 days after the index date (N=116,359).  
Ale= 5708, Ris= 2742, None= 101,404; 
Women without any OP treatment before 
the index date (N=43,290). 
Ale= 3,717, Ris= 1625, None= 37,948 
1. Women without 1-year continuous 
enrollment before and after the index date 
2. Women without any FRAX factors 
within a year before the index date  
3. Women without diagnosis of Paget 
disease and Malignancy  
(N=601,119) 
Women who initiated an OP drug other 
than the study drugs (N=19,005) 
Women with any OP drugs other than the 
study drugs within 12 months before the 
index date (N=66,564) 
OP: osteoporosis 
FRAX: Fracture Risk Assessment Tool  
Ale: Alendronate 
Ris: Risedronate 
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Figure 2-2: Choice of Alendronate vs. Non OP Treatment before and after Generic 
Availability of Alendronate 
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Figure 2-3: Choice of Alendronate vs. Risedronate before and after Generic 
Availability of Alendronate 
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Table 2-1: Characteristics of the Study Population * 
Total 37,948  
Age (mean, sd) 65.26 (11.34) 
DCG/HCC    
      Mean (Sd) 0.86  (0.75) 
      Median( 25th – 75th 
percentile) 
0.64 (0.38-1.07) 
History of fracture 3499 (8.08) 
Drugs that cause osteoporosis   
     Glucocorticoid 30407 (70.24) 
     H2 inhibitor 2196 (5.07) 
     Proton pump inhibitor 14129 (32.64) 
     Thyroid drug 9314 (21.52) 
Drugs associated with fracture   
    Benzodiazepine 10838 (25.04) 
    SSRI/Non-SSRI 13427 (31.02) 
    Anticonvulsant 4060 (9.38) 
    Hypnotics 7825 (18.08) 
    B blocker 11644 (26.90) 
    Thiazide 4168 (9.63) 
    NSAIDS/Cox-2 inhibitor 13354 (30.85) 
Health Plan type   
    Comprehensive 16428 (37.95) 
    HMO 4906 (11.33) 
    POS 2922 (6.75) 
    PPO 19034 (43.97) 
Geography   
    North Central 14701 (33.96) 
    Northeast 5274 (12.18) 
    South 16074 (37.13) 
    West 7050 (16.29) 
Health service utilization   
    Hospitalization 8658 (20.00) 
    Mammogram 16009 (36.98) 
* Data are given as number (percentage) unless otherwise indicated.  
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  
SSRI=selective serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-
inflammatory drug;  Cox-2=cyclooxygenase-2; HMO=Health Maintenance 
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Organization; POS=Point of Service; PPO=Preferred Provider Organization 
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Table 2-2: Strength of the IV Based on Generic Alendronate Availability in 
Comparative Effectiveness Research of Bisphosphonates* 
 Partial F statistic Partial R square P  
No osteoporosis treatment vs. 
alendronate 
5.34 0.0001 <0.05 
Alendronate vs. risedronate 301.99 0.0538 <0.01 
* Adjusting for covariates including demographics, osteoporosis related factors, co-
morbidity, medications, health services utilization, region of residence and health plan 
types. 
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Table 2-3: Characteristics of Women Initiating an Alendronate or No Osteoporosis Treatment* 
 Treatment assignment Instrumental variable 
 No-OP treatment Alendronate 
Std. 
Dif 
Before Feb, 2008 After Feb, 2008 
Std. 
Dif 
Total 37948 3717  22058 19607  
Age (mean, Sd)           
 65.00 (11.34) 67.20 (11.20) -0.195 65.69 (11.44) 64.60 (11.21) 0.096 
DCG/HCC            
      Mean (Sd) 0.86  (0.75) 0.87  (0.73) -0.014 0.87  (0.76 ) 0.84 (0.74)  0.040 
History of fracture 2904 (7.65) 425 (11.43) 0.129 1721 (7.80) 1608 (8.20) 0.015 
Drugs that cause osteoporosis          
     Glucocorticoid 26689 (70.33) 2595 (69.81) 0.011 15194 (68.88) 14090 (71.86) 0.065 
     H2 inhibitor 1946 (5.13) 176 (4.74) 0.018 1045 (4.74) 1077 (5.49) 0.034 
     PPI 12499 (32.94) 1118 (30.08) 0.062 7120 (32.28) 6497 (33.14) 0.018 
     Thyroid drug 8269 (21.79) 723 (19.45) 0.058 4731 (21.45) 4261 (21.73) 0.007 
Drugs associated with fracture          
    Benzodiazepine 9526 (25.10) 898 (24.16) 0.022 5523 (25.04) 4901) (25.00) 0.001 
    SSRI/Non-SSRI 11813 (31.13) 1124 (30.24) 0.019 6780 (30.74) 6157 (31.40) 0.014 
    Anticonvulsant 3577 (9.43) 336 (9.04) 0.013 1997 (9.05) 1916 (9.77) 0.025 
    Hypnotics 6898 (18.18) 616 (16.57) 0.043 4060 (18.41) 3454 (17.62) 0.021 
    B blocker 10257 (27.03) 988 (26.58) 0.010 5903 (26.76) 5342 (27.25) 0.011 
    Thiazide 3679 (9.69) 344 (9.25) 0.015 2110 (9.57) 1913 (9.76) 0.006 
    NSAIDS/Cox-2 inhibitor 11743 (30.94) 1120 (30.13) 0.018 6569 (29.78) 6294 (32.10) 0.050 
Health Plan type           
    Comprehensive 14948 (39.39) 996 (26.80) 0.270 8871 (40.22) 7073 (36.07) 0.086 
    HMO 4130 (10.88) 591 (15.90) 0.148 2195 (9.95) 2526 (12.88) 0.092 
    POS 2551 (6.72) 261 (7.02) 0.012 1359 (6.16) 1453 (7.41) 0.050 
    PPO 16319 (43.00) 1869 (50.28) 0.146 9633 (43.67) 8555 (43.63) 0.001 
Geography           
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    North Central 12787 (33.70) 1360 (36.59) 0.061 7725 (35.02) 6422 (32.75) 0.048 
    Northeast 4721 (12.44) 365 (9.82) 0.083 2789 (12.64) 2297 (11.72) 0.028 
    South 14129 (37.23) 1294 (34.81) 0.050 8219 (37.26) 7204 (36.74) 0.011 
    West 6133 (16.16) 688 (18.51) 0.062 3250 (14.73) 3571 (18.21) 0.094 
Health service utilization           
    Hospitalization 7536 (19.86) 773 (20.80) 0.023 4451 (20.18) 3858 (19.68) 0.013 
    Mammogram 14067 (37.07) 1369 (36.83) 0.005 8077 (36.62) 7359 (37.53) 0.019 
* Data are given as number (percentage) unless otherwise indicated.  
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective serotonin reuptake inhibitor; NSAIDS=non-
steroidal anti-inflammatory drug;  Cox-2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of Service; 
PPO=Preferred Provider Organization 
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Table 2-4: Characteristics of Women Initiating an Alendronate or Risedronate * 
 Treatment assignment Instrumental variable 
 Risedronate Alendronate 
Std. 
Dif 
Before Feb, 
2008 After Feb, 2008 
Std. Dif 
Total 1625  3717   3126  2216   
Age (mean, sd) 67.30 (10.97) 67.20 (11.20) 0.009 67.4 (11.06) 66.97 (11.21) 0.039 
DCG/HCC            
     Mean (SD) 0.89 (0.75) 0.87 (0.73) 0.027 0.89 (0.76) 0.85 (0.70) 0.055 
History of fracture 170 (10.46) 425 (11.43) 0.031 345 (11.04) 250 (11.28) 0.008 
Drug that cause osteoporosis     
 
    
     Glucocorticoid 1123 (69.11) 2595 (69.81) 0.015 2117 (67.72) 1601 (72.25) 0.099 
     H2 inhibitor 74 (4.55) 176 (4.74) 0.009 139 (4.45) 111 (5.01) 0.026 
     Proton pump inhibitor 512 (31.51) 1118 (30.08) 0.031 975 (31.19) 655 (29.56) 0.035 
    Thyroid drug 322 (19.82) 723 (19.45) 0.009 592 (18.94) 453 (20.44) 0.038 
Drugs associated with fracture     
0.031 
    
    Benzodiazepine 414 (25.48) 898 (24.16) 0.031 780 (24.95) 532 (24.01) 0.022 
    SSRI/Non-SSRI 490 (30.15) 1124 (30.24) 0.002 957 (30.61) 657 (29.65) 0.021 
    Anticonvulsant 147 (9.05) 336 (9.04) 0.000 279 (8.93) 204 (9.21) 0.010 
    Hypnotics 311 (19.14) 616 (16.57) 0.067 547 (17.50) 380 (17.15) 0.009 
    B blocker 399 (24.55) 988 (26.58) 0.047 833 (26.65) 554 (25.00) 0.038 
    Thiazide 145 (8.92) 344 (9.25) 0.011 288 (9.21) 201 (9.07) 0.005 
    NSAIDS/Cox-2 inhibitor 491 (30.22) 1120 (30.13) 0.002 917 (29.33) 694 (31.32) 0.043 
Health Plan type           
    Comprehensive 484 (29.78) 996 (26.80) 0.066 879 (28.12) 601 (27.12) 0.022 
    HMO 185 (11.38) 591 (15.90) 0.132 388 (12.41) 388 (17.51) 0.143 
    POS 110 (6.77) 261 (7.02) 0.010 224 (7.17) 147 (6.63) 0.021 
    PPO 846 (52.06) 1869 (50.28) 0.036 1635 (52.30) 1080 (48.74) 0.071 
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Geography           
    North Central 554 (34.09) 1360 (36.59) 0.052 1116 (35.70) 798 (36.01) 0.006 
    Northeast 188 (11.57) 365 (9.82) 0.057 352 (11.26) 201 (9.07) 0.073 
    South 651 (40.06) 1294 (34.81) 0.109 1173 (37.52) 772 (34.84) 0.056 
    West 229 (14.09) 688 (18.51) 0.120 478 (15.29) 439 (19.81) 0.119 
Health service utilization           
    Hospitalization 349 (21.48) 773 (20.80) 0.017 687 (21.98) 435 (19.63) 0.058 
    Mammogram 573 (35.26) 1369 (36.83) 0.033 1150 (36.79) 792 (35.74) 0.022 
* Data are given as number (percentage) unless otherwise indicated.  
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective serotonin reuptake inhibitor; NSAIDS=non-steroidal 
anti-inflammatory drug;  Cox-2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of Service; PPO=Preferred Provider 
Organization 
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Table 2-5: Non-vertebral Fracture at 3 Months Stratified by Different Treatment Groups and the Two 
Levels of the IV among Women at Risk for Osteoporotic Fracture* 
 No OP treatment vs. Alendronate 
3-month non-
vertebral fracture 
(%) 
 
Original treatment assignment IV 
No OP 
treatment 
Alendronate Std. dif Before Feb, 
2008 
After Feb, 
2008 
Std. dif 
0.88 0.79 0.24 0.88 0.86 0.06 
  
Alendronate vs. Risedronate 
Original treatment assignment IV 
Alendronate Risedronate Std. dif Before Feb, 
2008 
After Feb, 
2008 
Std. dif 
0.79 0.96 0.53 0.83 0.86 0.08 
* All comparison are not statistically significant (P>0.05) 
Std. dif = standard difference 
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3 CHAPTER III: COMPARATIVE EFFECTIVENESS OF 
ALENDRONATE AND RISEDRONATE ON NON-
VERTEBRAL FRACTURES: AN INSTRUMENTAL 
VARIABLES ANALYSIS 
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3.1 Introduction 
Osteoporosis is a skeletal disorder leading to increased risk of fractures in older 
people.8  About 54% women, age 50 or older, will have osteoporosis-related fractures 
during the course of their lives.11  Bisphosphonates are the leading pharmacologic 
treatment for osteoporosis and prevention of osteoporotic fractures.4  Among all 
bisphosphonates, alendronate and risedronate are the most commonly prescribed agents4, 
38. While randomized control trials (RCTs) have shown that both agents reduce the risk of 
non-vertebral fractures, evidence from head-to-head trials comparing alendronate and 
risedronate is lacking due to substantial logistic and financial burdens.37  Nevertheless, 
the comparative effectiveness of the two agents is important because alendronate (brand 
name: Fosamax) is available in a generic form and risedronate (brand name: Actonel) is 
not.  
Observational studies can provide meaningful information on the comparative 
effectiveness of the two medications on the risk of non-vertebral fractures.  Watts et al.36 
and Silverman et al.3 found significant risk reduction for risedronate vs. alendronate in 
women, 65 years of age or older, at 6, 12 and 24 months (HR ranged from 0.41 to 0.82).  
However, Cutis et al.37 and Cadarette et al.38 showed the difference in the risk of non-
vertebral fracture between older women (65 years or older) on risedronate and 
alendronate was small and not statistically significant (HR ranged from 0.96 to 1.07).  
Despite using similar observational study designs, statistical analyses and confounding 
adjustments, inconsistent results appeared in these studies.  One possible explanation for 
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such an inconsistency is that observational studies may suffer from confounding bias 
from unmeasured variables.3, 37  Studies applying methods to adjust for potential 
unmeasured confounding can provide further information on the comparative 
effectiveness of these medications38.  
Instrumental variables (IV) analysis, recently introduced to medical research, is a 
methodological approach used to reduce bias due to unmeasured confounding.6  It has 
been demonstrated to provide estimates of effect comparable to those from RCTs.48  
Therefore, we conducted a head-to-head comparison between alendronate and risedronate 
on the risk of non-vertebral fractures using observational data and an IV analysis.  We 
hypothesize that alendronate has a comparable effect to risedronate on the risk of one-
year non-vertebral fracture in women, 50 years of age or older.  We propose a new IV 
based on generic utilization of alendronate which may be used for comparative 
effectiveness research of other prescription drugs. 
3.2 Methods 
3.2.1 Data Source 
This study used the Medstat MarketScan Commercial Claims and Encounters 
(CCE) and Medicare Supplemental Database (Ann Arbor, MI).  Data were available for 
2005-2009 and partial for 2010.  The MarketScan database captures the largest 
convenient sample of over 107 million unique patients.  Since 1996, it has collected 
information mostly from large employers in the U.S.71, 72  This nationwide database 
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contains over 500 million claim records per year from individuals with employer-
sponsored health insurance.  Information captured in the database includes patient 
demographics, detailed enrollment, inpatient services, physician encounters and 
pharmacy claims.  Scientific studies based on this data source have been reported in more 
than 75 peer-reviewed articles71. 
3.2.2 Study Design and Population 
We conducted a retrospective cohort study and adopted a new user design.75  
Figure 3-1 shows the sample selection strategy.  We selected women, 50 years of age or 
older, who had enrollment information between 2007 and 2009 (N=8,034,624).  We then 
identified women who initiated an oral alendronate (10mg or 70mg) or risedronate (5mg 
or 35mg) during the time period and had continuous enrollment before and after the index 
date ─ date of initiation of an alendronate or risedronate (N=360,857).  Individuals were 
excluded if: 1) they had a bisphosphonate within 12 months before the index date 
(N=249,048); and 2) they had a diagnosis of Paget’s disease (ICD-9-CM code: 731.0) or 
malignant neoplasm (ICD-9-CM: 140-208) within one year before the index date 
(N=11,496). The final sample included 100,313 women, among whom 71,034 initiated 
an alendronate and 29,279 risedronate. 
3.2.3 Measures 
Outcomes 
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The main outcome variable was an indicator of non-vertebral fracture (including 
hip, wrist/forearm and proximal humerus).  It was identified during the first 6 and 12 
months following the index date.  We used diagnostic and procedure codes from claims 
to identify non-vertebral fractures based on approaches described by previous research38, 
78 (appendix I shows diagnostic and procedure codes).  
Main Exploratory Variable 
The main exploratory variable was an indicator of alendronate (10mg or 70mg) or 
risedronate (5mg or 35mg).  We identified alendronate or risedronate using national drug 
code (NDC) and appendix II shows the codes.  
Covariates 
We determined patient demographic characteristics at the index date and other 
characteristics using claims from inpatient services, outpatient services and pharmacy 
claims within 12 months before the index date (appendix III).  The characteristics 
included: 1) patient demographic (age); 2) history of non-vertebral fracture and diagnosis 
of osteoporosis; 3) co-morbidity measured by the Diagnostic Cost Group Hierarchical 
Condition Category (DCG/HCC) classification system (DxCG, Boston, MA)88; 4) co-
medications (drugs that may cause osteoporosis, treat/prevent osteoporosis and drugs 
associated with fracture); 5) health services utilization (hospitalization and screening 
mammogram); 6) geographic location of primary beneficiary’s residence; and 7) types of 
health plans.  
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We measured patient’s age in years. For patient history, a diagnosis of 
osteoporosis was defined as having a diagnostic code of 733.0x.38  We defined history of 
non-vertebral fracture as having a diagnosis of hip fracture, wrist/forearm or proximal 
humerus within a year prior to the index date.  We measured co-morbid condition using 
the DCG/HCC classification system.  The DCG/HCC risk adjuster creates a single score 
for each person based on the presence of 189 medical conditions in the diagnosis fields of 
claims records.  Despite its development for Medicare billing purpose, the DCG/HCC has 
been widely applied as a measure of confounding in studies of drug use.89  We grouped 
concomitant medications based on their relationships with osteoporosis and fracture. 
Drugs that may cause osteoporosis included glucocorticoids90, H2 inhibitors, proton 
pump inhibitors (PPI)91 and thyroid medications.92  Drugs that treat or prevent 
osteoporosis included calcitonin, vitamin D, estrogen, selective estrogen receptor 
modulator (SERM) and parathyroid hormone.15  Drugs that may be associated with 
fracture included psychotropic medications (benzodiazepine, selective serotonin reuptake 
inhibitor [SSRI], non-SSRI antipsychotic, anticonvulsant and hypnotics)93, cardiovascular 
medications (beta blocker and thiazide)94, 95, and anti-inflammatory drugs (non-steroidal 
anti-inflammatory drug [NSAID] and cyclooxygenase 2 [COX2] inhibitor).  Health 
services utilization variables included any hospitalization and any screening mammogram 
as proxy for health behavior.  We categorized geographic location of primary 
beneficiary’s residence into north central, northeast, south and west.  Types of health 
plans included comprehensive plan, health maintenance organization (HMO), point of 
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service (POS), and preferred provider organization (PPO).  A detailed list of covariates 
can be found in the appendix III.  
Instrumental Variables 
We adopted an instrumental variable approach to address confounding from 
unmeasured variables.  The instrumental variable we used was based on calendar time, 
specifically, the date of generic alendronate availability (February 1, 2008). 
An instrument variable is valid if it meets two key assumptions: 1) the IV should 
be associated with the treatment assignment and 2) the IV has no relationship with 
measured and unmeasured confounders and does not directly cause the outcome6, 44.  
Theoretically, the date of generic alendronate availability satisfies the two key 
assumptions.  First, the use of a drug will increase after its patent protection expires 
partially because of the price drop.97  Generic alendronate has been on the market since 
February 1, 2008, while the patent of Actonel (brand name for risedronate) has not 
expired yet.  Therefore, the use of alendronate in comparison to risedronate would 
increase after alendronate went generic.  Second, a historical date is independent of the 
characteristics of a population because they do not change dramatically over a short time 
period. In addition, a historical date does not affect patient outcome.  Therefore the date 
of generic alendronate availability meets the second assumption.  
3.2.4 Statistical Analysis 
Descriptive Statistics 
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We presented means and standard deviations for continuous variables, and 
frequencies and proportions for discrete variables.  We described the distribution of 
patient characteristics by the original treatment assignment (alendronate and risedronate) 
and then by two levels of the IV (before and after February 1, 2008).  We graphed the 
trend of the use of alendronate in the study sample over time (Figure 3-2). 
Conventional univariate and multivariate analyses 
We examined the crude association between study bisphosphonates and non-
vertebral fracture outcome at 6 and 12 months using simple linear regressions.  In the 
multiple linear regressions, we assessed the association adjusting for variables described 
in the covariates section.  We reported risk difference (RD) from the linear regressions. 
We chose linear regression because it estimated RDs which were comparable to IV 
estimates and have been applied in previous research.45, 98 
Instrumental Variables (IV) Analysis  
We used a 2-stage least square (2SLS) regression for the IV analysis and RD was 
reported per 100 patients.  We built two simultaneous equations (equation 1 and 2). In the 
first stage (equation 1), we regressed the treatment variable on the IV and other measured 
covariates.  In equation 1, E[T|IV] indicates the expected value of the treatment 
assignment for the ith patient given the IV after controlling for measured covariates.  T 
equals 1 when the patient receives an alendronate and 0 otherwise.  IV is the date of 
generic alendronate availability.  It equals 1 when the date is after February 1, 2008 and 0 
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otherwise.  X is a vector of measured covariates.  ˆ 1 estimates the increase of the 
probability of initiating an alendronate after it turns generic adjusting for other measured 
covariates. 
In the second stage (equation 2), we regressed the outcome on the expected values 
of treatment assignment (E[T|IV]) obtained from the first stage and other measured 
covariates.  Yi represents the outcome of the ith patient, an indicator of non-vertebral 
fracture.  It equals 1 when a patient has at least one non-vertebral fracture and 0 
otherwise. 
ˆ 1is the IV estimator.  
Equation (1) 

m
j jijiii
XIVXIVTIVTE
2=10,
)|1Pr(]|[   
Equation (2) 
E[Y | IV]Pr(Yi 1|Pr(Ti 1| IVi,Xi),Xi) 0 1Pr(Ti 1| IVi,Xi)  jX ji
j=2
m
  
All analyses were performed using STATA 10. We used IVREG2 for the IV 
analysis. The study was approved by the Institutional Review Board of the University of 
Massachusetts Medical School. 
3.3 Results 
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We identified 100,313 women, among whom 71,034 initiated an alendronate and 
29,279 risedronate. Among women instantiating an alendronate, 2.04 % (n=1449) and 
2.89% (n=2,053) had a non-vertebral fracture in the following 6 and 12 months 
respectively, while they were 1.85% (n=542) and 2.69% (n=789) for women initiating a 
risedronate in the following 6 and 12 months respectively. We also stratified the sample 
by the date of the generic availability of alendronate. There were 61,757 women who 
initiated a study bisphosphonate before February 1, 2008 and 38,556 after. Among 
women initiating a bisphosphonate before February 1, 2008, 1.87% (n=1,156) and 2.69% 
(n=1,661) had a non-vertebral fracture at 6 and 12 months respectively. Among women 
initiating a bisphosphonate after February 1, 2008, 2.17% (n=835) and 3.06% (n=1,181) 
had a non-vertebral fracture at 6 and 12 months respectively (Appendix IV). 
Table 3-1 shows the distribution of patient characteristics stratified by the 
original treatment assignment (alendronate or risedronate). In general, differences in 
patient characteristics between the two treatment groups are relatively small, although 
most p values are less than 0.05 due to large sample size. Compared to patients taking 
risedronate, those taking alendronate were relatively older (mean age: 65 vs. 64); had a 
higher proportion of fracture history (3.68% vs. 3.30) and diagnosis of osteoporosis 
(33.63% vs. 32.00%).  Patients taking alendronate also received relatively more 
medications.  However, the distribution of vitamin D is substantially imbalanced between 
the two groups (22.99% vs. 3.07%).  For health services utilization, alendronate users had 
more hospitalizations (12.27% vs. 11.75%) and fewer screening mammograms (52.68% 
vs. 55.60%). More patients taking alendronate lived in West, while more risedronate 
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users lived in the South. Compared to risedronate users, alendronate users had a relatively 
higher proportion of enrollment in HMOs and a lower proportion of enrollment in PPOs.  
Table 3-2 shows the distribution of patient characteristics before and after the 
availability of generic alendronate, February 1, 2008.  In general, differences in patient 
characteristics between the two levels of the IV are also relatively small, although most p 
values are less than 0.05 due to large sample size. The IV provides more balance in some 
characteristics such as vitamin D (19.00% vs. 14.25%), parathyroid hormone (1.20% vs. 
1.19%), calcitonin (1.56% vs. 1.61%) and screening mammogram (54.20% vs. 52.47%). 
Some characteristics are less balanced between the two levels of the IV such as thyroid 
drug (18.04% vs. 19.46%), benzodiazepine (16.72% vs.18.57%) and hypnotics (12.10% 
vs. 13.01%).  
Figure 3-2 shows the choice of alendronate or risedronate before and after the 
availability of generic alendronate. We found that among all patients in the sample, 
approximately 60% initiated alendronate in January 2007 and the use of alendronate did 
not change before February 1, 2008.  After generic alendronate became available on 
February 1, 2008, the use of this medication increased dramatically with 92% of the 
sample initiating alendronate by May 2009.  In contrast, the use of risedronate did not 
change before February 1, 2008; however, it decreased after.  
Table 3-3 shows the unadjusted and adjusted association between alendronate in 
relative to risedronate on the risk of non-vertebral fractures using conventional simple 
and multiple linear regressions.  At 6 months, compared to women with risedronate, those 
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with alendronate had higher risk of non-vertebral fracture (unadjusted RD, 0.19 per 100 
women, confidence interval [CI], -0.00-0.38 per 100 women).  After adjusting for patient 
characteristics, the RD decreased (adjusted RD, 0.12 per 100 women, 95%CI -0.06-0.30 
per 100 women).  At 12 months, we found that women taking alendronate had higher but 
not significant risk of non-vertebral fracture compared with women taking risedronate 
(unadjusted RD, 0.20 per 100 women; 95%CI, -0.03-0.42 per 100 women).  Adjusting for 
patient characteristics did not change the association (adjusted RD, 0.10 per 100 women; 
95% CI, -0.12-0.31per 100 women).  In the IV analysis, the first stage partial R square 
was 0.04 and F statistic was 3953.40 indicating a strong IV.  The IV analysis showed 
similar findings (Table 3-3).  Using risedronate as the reference, alendronate showed a 
subtle but not significant increase in the risk of non-vertebral fracture at 6 months (RD, 
0.17 per 100 women; 95%CI, -0.76-1.10 per 100 women).  The association did not 
change at 12 months (RD, 0.27 per 100 women; 95%CI, -0.86-1.14 per100 women).  
3.4 Discussion 
We compared the effect of alendronate with risedronate on the risk of one-year 
non-vertebral fractures in women, 50 years or older, using claims data from multiple 
health plans across the US. Our conventional analysis showed a comparable effect of 
alendronate vs. risedronate on the risk of non-vertebral fractures (at 6 months: adjusted 
RD = 0.12 per 100 women, 95%CI [-0.06-0.30]; at 12 months: adjusted RD = 0.10 per 
100 women, 95%CI [-0.12-0.31]).  The results of the IV analysis were consistent with 
those from the conventional analysis (at 6 months: RD=0.17 per 100 women, 95%CI [-
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0.76-1.10]; at 12 months: RD=0.27 per 100 women, 95%CI [-0.86-1.14].  As an ad hoc 
analysis we excluded women who had a history of non-vertebral fracture in the analysis 
because patients with a history of fracture may react differently to osteoporosis treatment 
for patients without a history of fracture.  We found similar results; therefore we reported 
the analysis include the fracture history.  Our results are consistent with the two latest 
observational studies by Curtis et al.37 and Caderette et al.38.   
However, our results differ from findings of two earlier studies by Watts et al.36 
and Silverman et al.3 Methodological differences in study design and analysis may 
partially explain such discordance. First, we limited our study to alendronate and 
risedronate approved for osteoporosis treatment purpose, while the others included doses 
for prevention. Second, we defined our patient characteristics using data at baseline and 
one year historical period, while Watts et al. assessed patient characteristics at baseline 
and Silverman et al. at baseline and 6-month historical period. Finally we included 
women, 50 years of age or older, while the others included women who were at least 65 
years of age. The inclusion of younger and possibly healthier women increased the 
generalizability of our results. It might, however, affect our results towards null. As a 
post hoc analysis, we repeated our analysis on women, 65 years of age or older and found 
similar estimates.  
One important improvement of our study compared with previous studies is that 
we applied an econometric method to account for unmeasured confounding that had not 
been fully addressed by previous studies. IV analysis has gained popularity in 
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comparative effectiveness research of prescription medications46. A valid IV needs to 
meet two key assumptions: 1) the IV is associated with the treatment assignment; 2) it is 
independent of measured and unmeasured confounders and has not direct effect on the 
outcome. Our IV, the date of generic availability of alendronate, is valid. First, we 
reasoned that cost reduction of Fosamax (brand name of alendronate) after the generic 
form was on the market might be a factor affecting decision of initiating an alendronate 
or a risedronate. We provided empirical evidence showing that the probability of 
initiating an alendronate increased significantly after its generic availability (Figure 3-2). 
Furthermore, such an increase was attributable to the generic utilization. More than 90% 
of alendronate initiated by May 2009 were in generic form (data not shown). Second, it is 
impossible to directly verify the second assumption. Brookhart81 suggested that the IV 
should provide balance for measured confounders.  We reported that patient 
characteristics were quite evenly distributed between the two levels of the IV.  We did 
not see a substantial reduction in imbalance of patient characteristics by the IV because 
patient characteristics were already evenly distributed between original treatment 
assignments.  However, we reported the IV analysis because it provided further 
adjustment for unmeasured confounders.  Finally, theoretical foundation of the IV 
proposed in this paper may be used for comparative effectiveness research of mediation 
other than alendronate.  It is particularly usefully for medications that have strong 
confounding by indication 
This study is also subject to limitations.  First, we identified non-vertebral fracture 
outcome using claims data.  Potential misclassification was possible.  However, our 
   74 
  
approach of identifying non-vertebral fractures has been applied by other research and 
study has shown that using claims data to identify fracture outcomes will achieve 90% 
sensitivity if medical records are the reference standard77.  Second, the study was limited 
to employed women who had employer-sponsored insurance.  The result is not 
generalizable to unemployed or uninsured women.  Third, although patient characteristics 
were evenly distributed between two levels of the IV, the IV did not show a significant 
reduction in imbalance of these characteristics.  This might be due to the inclusion of 
insured women in this study.  A study including samples from uninsured women might 
improve the IV analysis because they may be more sensitive to price of a medication and 
have different characteristics from the insured.  Finally, our results should be explained in 
the context of observational study. A randomized trial is warranted to provide better 
evidence.  
In conclusion, the reduction in the risk of one-year non-vertebral fractures is 
comparable between alendronate and risedronate in women 50 years of age or older.  The 
IV based on the time of generic form availability may be useful for comparative 
effectiveness research of prescription drugs in general. 
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Women, ≥ 50 yrs, who had enrollment 
information between 2007 and 2009 
(N=8,034,624) 
Women with 1 year continuous enrollment before 
and after initiation of an alendronate or 
risedronate (N=360,857):  
Aln (n=255,612); Ris (n=105,245) 
 
Women who  
1) did not initiate an alendronate or 
risedronate  
or  
2) did not have two years continuous 
enrollment before and after the index 
date if they initiated an alendronate 
or risedronate 
 
(N=7,673,767) 
Women who  
1) had any bisphosphonates 
within one year before the 
index date  
 
 (N=249,048) 
Aln (n=176,242), Ris (n=72,806) Women who were new alendronate or risedronate 
users (N=111,809) 
Aln (N=79,370), Ris (N=32,439) 
 
Study sample (N=100,313) 
Aln=71,034; Ris=29279 
 
    
 
Women who had Paget’s disease or 
malignancy within a year before the index 
date (N=11,496). 
 
    
 
Figure 3-1: Sample Selection Strategy * 
 
*Aln=Alendronate, Ris =Risedronate 
Exclude  
Exclude  
Exclude  
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Table 3-1: Characteristics of Women Initiating an Alendronate or Risedronate Between 
2007 and 2009* 
 Alendronate  Risedronate 
N of patients 71034  29279  
Demographics     
  Age 65 (10.77) 64 (10.76) 
History     
  History of non-vertebral fracture 2613 (3.68) 966 (3.30) 
  Osteoporosis  23889 (33.63) 9370 (32.00) 
Co-morbidity (DCG/HCC) 0.6 (0.51) 0.6 (0.54) 
Drug that cause osteoporosis     
   Glucocorticoid 18000 (25.34) 7274 (24.84) 
   H2 inhibitor 2894 (4.07) 983 (3.36) 
   Proton pump inhibitor 15673 (22.06) 6724 (22.97) 
   Thyroid drug 13187 (18.56) 5459 (18.64) 
Drugs that treat/prevent osteoporosis     
   Vitamin D 16332 (22.99) 898 (3.07) 
   Estrogen 9289 (13.08) 4144 (14.15) 
   SERMS 2847 (4.01) 1206 (4.12) 
   Parathyroid hormone 805 (1.13) 395 (1.35) 
   Calcitonin 1054 (1.48) 532 (1.82) 
Drugs associated with fracture     
   Benzodiazepine 12442 (17.52) 5041 (17.22) 
   SSRI/Non-SSRI 19322 (27.20) 7814 (26.69) 
   Anticonvulsant 5052 (7.11) 1940 (6.63) 
   Hypnotics 8749 (12.32) 3736 (12.76) 
   B blocker 15336 (21.59) 6002 (20.50) 
   Thiazide 6618 (9.32) 2287 (7.81) 
   NSAIDS/Cox-2 inhibitor 18256 (25.70) 7001 (23.91) 
Health service utilization     
   Hospitalization 8714 (12.27) 3439 (11.75) 
   Mammogram 37422 (52.68) 16279 (55.60) 
Geography¶     
   North Central 22619 (31.84) 9832 (33.58) 
   Northeast 6213 (8.75) 2526 (8.63) 
   South 25799 (36.32) 12500 (42.69) 
   West 16219 (22.83) 4352 (14.86) 
Health Plan type¶     
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   Comprehensive 14034 (19.76) 5976 (20.41) 
   HMO 13340 (18.78) 3660 (12.50) 
   POS 5806 (8.17) 2441 (8.34) 
   PPO 36857 (51.89) 16765 (57.26) 
* Data are given as number (percentage) unless otherwise indicated.  
¶ Numbers in cells are proportion and 95%CI  
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective serotonin 
reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory drug;  Cox-2=cyclooxygenase-2; 
HMO=Health Maintenance Organization; POS=Point of Service; PPO=Preferred Provider 
Organization 
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Table 3-2: Characteristics of women before and after generic availability of alendronate, 
February 1,2008 * 
 Before Feb, 2008 After Feb, 2008 
N of patients 61757  38556  
Demographics     
  Age (mean, sd) 64 (10.67) 65 (10.89) 
History of non-vertebral fracture 2065 (3.34) 1514 (3.93) 
Osteoporosis  20014 (32.41) 13245 (34.35) 
Co-morbidity (DCG/HCC)   (mean, sd) 0.59 (0.53) 0.61 (0.52) 
Drug that cause osteoporosis     
   Glucocorticoid 14942 (24.19) 10332 (26.80) 
   H2 inhibitor 2038 (3.30) 1839 (4.77) 
   Proton pump inhibitor 13445 (21.77) 8952 (23.22) 
   Thyroid drug 11144 (18.04) 7502 (19.46) 
Drugs that treat/prevent osteoporosis     
   Vitamin D 11736 (19.00) 5494 (14.25) 
   Estrogen 8552 (13.85) 4881 (12.66) 
   SERMS 2470 (4.00) 1583 (4.11) 
   Parathyroid hormone 743 (1.20) 457 (1.19) 
   Calcitonin 964 (1.56) 622 (1.61) 
Drugs associated with fracture     
   Benzodiazepine 10323 (16.72) 7160 (18.57) 
   SSRI/Non-SSRI 16337 (26.45) 10799 (28.01) 
   Anticonvulsant 4051 (6.56) 2941 (7.63) 
   Hypnotics 7470 (12.10) 5015 (13.01) 
   B blocker 12540 (20.31) 8798 (22.82) 
   Thiazide 5222 (8.46) 3683 (9.55) 
   NSAIDS/Cox-2 inhibitor 14921 (24.16) 10336 (26.81) 
Health service utilization     
   Hospitalization 7244 (11.73) 4909 (12.73) 
   Mammogram 33470 (54.20) 20231 (52.47) 
Geography¶     
   North Central 20799 (33.68) 11652 (30.22) 
   Northeast 5388 (8.72) 3351 (8.69) 
   South 23876 (38.66) 14423 (37.41) 
   West 11541 (18.69) 9030 (23.42) 
Health Plan type¶     
   Comprehensive 12292 (19.90) 7718 (20.02) 
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   HMO 9009 (14.59) 7991 (20.73) 
   POS 4735 (7.67) 3512 (9.11) 
   PPO 35129 (56.88) 18493 (47.96) 
* Data are given as number (percentage) unless otherwise indicated.  
¶ Numbers do not add to 100% because of missing data 
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective serotonin 
reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory drug;  Cox-2=cyclooxygenase-2; 
HMO=Health Maintenance Organization; POS=Point of Service; PPO=Preferred Provider 
Organization 
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Figure 3-2: Choice of Alendronate or Risedronate before and after Generic 
Alendronate Availability 
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Table 3-3: Comparing the Effect of Alendronate vs. Risedronate on the Risk of 
Non-vertebral Fractures in 12 Months* 
 6 months 12 months 
 RD 95%CI RD 95%CI 
Unadjusted (cases/100 patients) 0.19 -0.00-0.38 0.20 -0.03-0.42 
Adjusted (cases/100 patients) ¶ 0.12 -0.06-0.30 0.10 -0.12-0.31 
IV estimator (cases/100 patients) ¶ 0.17 -0.76-1.10 0.27 -0.86-1.14 
* Reference group = risedronate; RD=risk difference; CI=confidence interval; 
IV=instrumental variables 
¶Adjusting for covariates including demographic characteristics, osteoporosis related 
factors, co-morbidity, concomitant medications, health services utilization region of 
residence and health plan types.  
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4 CHAPTER IV: COMPARATIVE EFFECTIVENESS OF 
ALENDRONATE AND RISEDRONATE ON THE RISK 
OF NON-VERTEBRAL FRACTURES: USING TWO 
VALID INSTRUMENTAL VARIABLES 
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4.1 Introduction 
In February of 2008, the block buster prescription drug Fosamax (alendronate) 
became the first bisphosphonate to be available as a generic drug, which substantially 
reduces its cost (looking for data).  Bisphosphonates are a class of drugs that inhibitor 
bone resorption and are commonly prescribed for treatment and prevention of 
osteoporosis (OP) in postmenopausal women.1, 2, 15  However, despite the lower costs of 
generics, brand name prescribing of bisphosphonates still occurs -- as of the first quarter 
of 2009, among patients initiating a bisphosphonate, approximately 8% was for Actonel 
(risedronate) despite unclear evidence of any efficacy superiority (as discussed in Aim 2). 
There are no randomized controlled trials (RCTs) assessing the comparative 
effectiveness of the two bisphosphonates on the risk of non-vertebral fractures in older 
women.  Head-to-head trails using intermediate endpoints of bone mineral density 
(BMD) have shown that alendronate has slightly advantage over risedronate.15  
Therefore, evidence of the comparative effectiveness of alendronate vs. risedronate on 
the risk of non-vertebral fractures may provide important information for physicians and 
patients to choose a cost-effective strategy to treat osteoporosis and prevent osteoporotic 
fractures.  However, existing observational studies have shown inconsistent results.3, 36-38  
Two earlier studies showed that risedronate reduced more of the risk of one-year non-
vertebral fractures in postmenopausal women3, 36 while two later studies found 
comparable effects between the two bisphosphonates.37, 38  Unable to account for 
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confounding from unmeasured variables such as frailty and healthy behaviors may 
contribute to bias in comparative effectiveness studies of alendronate and risedronate.   
Instrumental variables (IVs) have been introduced as a way to address measured 
and unmeasured confounding in observational studies6 and the IV approach is gaining 
popularity in prescription drug research.46  The IV analysis can approximate 
randomization by identifying an IV or IVs that satisfy restricted assumptions: 1) the IV is 
highly associated with treatment choice; 2) is independent of measured and unmeasured 
cofounders and 3) does not directly cause a patient outcome.44, 99   
The objectives of this study were to 1) assess the comparative effectiveness of 
alendronate vs. risedronate on the risk of 12-month non-vertebral fractures in women 50 
years of age or older using an IV approach and 2) apply two IVs and compare their 
performance in evaluating the same question in the same population.  
4.2 Methods 
4.2.1 Data Source 
This study used the Medstat MarketScan Commercial Claims and Encounters 
(CCE) and Medicare Supplemental Database (Ann Arbor, MI).  Data were available for 
2005-2009 and partially for 2010.  The MarketScan database captures the largest 
convenient sample of over 73 million unique patients.  Since 1996, it has collected 
information mostly from large employers in the U.S. 71  This nationwide database 
contains over 500 million claim records per year from individuals with employer-
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sponsored health insurance.  Information captured in the database includes patient 
demographics, detailed enrollment, inpatient services, physician encounters and 
pharmacy claims.  Scientific studies based on this data source have been reported in more 
than 100 peer-reviewed articles71. 
4.2.2 Study Design and Population 
We conducted a retrospective cohort study and adopted a new user design.76  
Figure 4-1 shows the sample selection strategy.  We selected women, 50 years of age or 
older, who had enrollment information between 2007 and 2009 (N=8,034,624).  We then 
identified women who initiated an oral alendronate (10mg or 70mg) or risedronate (5mg 
or 35mg) during the time period and had continuous enrollment before and after the index 
date ─ date of initiation of an alendronate or risedronate (N=360,857).  Individuals were 
excluded if: 1) they had a bisphosphonate within 12 months before the index date and a 
bisphosphonate other than the study medications within 12 months after the index date 
(N=261,561); and 2) they had a diagnosis of Paget’s disease (ICD-9-CM code: 731.0) or 
malignant neoplasm (ICD-9-CM: 140-208) within one year before the index date 
(N=11,498).  Finally we restricted our sample to women who had information on 
physician preference.  The analytic sample included 3,190 women, among whom 2,332 
initiated an alendronate and 858 risedronate. 
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Outcome 
The main outcome variable was an indicator of non-vertebral fracture (including 
hip, wrist/forearm and proximal humerus) identified during the first 3 and 12 months 
following the index date. We used diagnostic and procedure codes from claims to identify 
non-vertebral fractures based on approaches described by previous research38, 78 
(appendix I shows diagnostic and procedure codes).  
Main Exploratory Variable 
The main exploratory variable was an indicator of alendronate (10mg or 70mg) or 
risedronate (5mg or 35mg). We identified alendronate or risedronate using the national 
drug code (NDC) and appendix II shows the codes.  
Covariates 
We determined patient demographic characteristics at the index date and other 
characteristics using claims from inpatient services, outpatient services and pharmacy 
claims within 12 months before the index date (appendix III). The characteristics 
included: 1) patient demographic (age); 2) history of non-vertebral fracture and diagnosis 
of osteoporosis; 3) co-morbidity measured by the Diagnostic Cost Group Hierarchical 
Condition Category (DCG/HCC) classification system (DxCG, Boston, MA)88; 4) co-
medications (drugs that may cause osteoporosis, treat/prevent osteoporosis and drugs 
associated with fracture); 5) health services utilization (hospitalization and screening 
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mammogram); 6) geographic location of primary beneficiary’s residence; and 7) types of 
health plans.  
We measured patient’s age in years. For patient history, a diagnosis of 
osteoporosis was defined as having a diagnostic code of 733.0x38. We defined history of 
non-vertebral fracture as having a diagnosis of hip fracture, wrist/forearm or proximal 
humerus within a year prior to the index date. We measured co-morbid condition using 
the DCG/HCC classification system. The DCG/HCC risk adjuster creates a single score 
for each person based on the presence of 189 medical conditions in the diagnosis fields of 
claims records. Despite its development for Medicare billing purpose, the DCG/HCC has 
been widely applied as a measure of confounding in studies of drug use89. We grouped 
concomitant medications based on their relationships with osteoporosis and fracture. 
Drugs that may cause osteoporosis included glucocorticoids90, H2 inhibitors, proton 
pump inhibitors (PPI)91 and thyroid medications92.  Drugs that treat or prevent 
osteoporosis included calcitonin, vitamin D, estrogen, selective estrogen receptor 
modulator (SERM) and parathyroid hormone15.  Drugs that may be associated with 
fracture included psychotropic medications (benzodiazepine, selective serotonin reuptake 
inhibitor [SSRI], non-SSRI antipsychotic, anticonvulsant and hypnotics)93, cardiovascular 
medications (beta blocker and thiazide)94, 95, and anti-inflammatory drugs (non-steroidal 
anti-inflammatory drug [NSAID] and cyclooxygenase 2 [COX2] inhibitor). Health 
services utilization variables included any hospitalization and any screening mammogram 
as proxy for health behavior. We categorized geographic location of primary 
beneficiary’s residence into north central, northeast, south and west. Types of health 
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plans included comprehensive plan, health maintenance organization (HMO), point of 
service (POS), and preferred provider organization (PPO).  A detailed list of covariates 
can be found in the appendix III.  
Instrumental Variables 
We used two IVs in this study. We have proposed a new IV for comparative 
effectiveness research in a previous paper (discussed in Aim 1).  The IV we used was 
based on calendar time, specifically, the date of generic alendronate availability.   
Fosamax (alendronate) went off patent protection in February 2008; so the IV was 
defined as an indicator of time before or after February 1, 2008.  Theoretically, the date 
of generic alendronate availability satisfies key assumptions of a valid IV.  First, the use 
of a drug will increase after its patent protection expires partially because of the drop in 
price.97 Generic alendronate has been on the market since February 2008, while the patent 
of Actonel (brand name for risedronate) has not expired yet.  Therefore, the use of 
alendronate in comparison to risedronate would increase after alendronate went generic.  
Second, a historical date is independent of the characteristics of a population because 
they do not change over a short time period.  In addition, a historical date does not 
directly cause patient outcome.  Therefore the date of generic alendronate availability is a 
valid IV. 
We also used a physician preference IV that has been applied in several studies 
examining the comparative effectiveness of prescription drugs (i.e. atypical vs. typical 
antipsychotics).48, 61, 63  We adapted a method based on Brookhart et al. to measure 
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physician preference 45 - namely the most recent new bisphosphonate prescription for a 
prescriber’s patient other than the present patient.  Since prescriber information was only 
available in inpatient and outpatient claims but not pharmacy claims, we develop restrict 
criteria to measure physician preference in our data.  We first identified the physician 
who saw the study patient at the index date.  We then identified all patients with at least 
one bisphosphonate prescription of the physician within a year before the index date.  
Finally, the closest bisphosphonate prescription to the index date was considered as the 
physician’s preference.  
4.2.3 Statistical Analysis 
Descriptive Statistics 
We presented means and standard deviations for continuous variables, and 
frequencies and proportions for discrete variables.  We described the distribution of 
patient characteristics by the original treatment assignment (alendronate and risedronate) 
and then by levels of the IVs.  We compared means using t-test and proportions using 
Chi-square test or Fisher’s exact test. 
Conventional Univariate and Multivariate analyses 
We examined the crude association between study bisphosphonates and non-
vertebral fracture outcome at 12 months using ordinary least squares linear regressions.  
We also conducted multiple linear regressions to assess the association adjusting for 
variables described in the covariates section.  We reported risk differences (RDs) from 
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the linear regressions.  The reason we chose linear regression instead of logistic 
regression was that linear reports RD which can be used to compare results between the 
conventional analyses and the IV analyses.48 
Instrumental Variables (IV) Analysis  
We used a 2-stage least square (2SLS) regression44 for the IV analysis and RDs 
were reported.  We presented the IV analysis for the calendar time IV as an example.  We 
built two simultaneous equations (equation 1 and 2).  In the first stage (equation 1), we 
regressed the treatment variable on the IV and other measured covariates. In equation 1, 
E[T|IV] indicates the expected value of the treatment assignment for the ith patient given 
the IV after controlling for measured covariates.  T equals 1 when the patient receives an 
alendronate and 0 otherwise. IV is the date of generic alendronate availability.  It equals 1 
when the date is after February 1, 2008 and 0 otherwise. X is a vector of measured 
covariates.  ˆ 1 estimates the increase of the probability of initiating an alendronate after it 
turns generic adjusting for other measured covariates. 
In the second stage (equation 2), we regressed the outcome on the expected values 
of treatment assignment (E[T|IV]) obtained from the first stage and other measured 
covariates.  Yi represents the outcome of the ith patient, an indicator of non-vertebral 
fracture.  It equals 1 when a patient has at least one non-vertebral fracture and 0 
otherwise.  
ˆ 1is the IV estimator.  
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Equation (1) 
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We also conducted the two stage residual inclusion (2SRI) for the IV analysis 
because studies have shown that the 2SRI is consistent in a generic parametric framework 
and it is robust to nonlinearity while the 2SLS is not.100  The difference between the 2SRI 
and 2SLS is that we do not replace the treatment variable with the expected values from 
the first stage regression. We, instead, adjust the residuals from the first stage in the 
second stage model.  We yielded similar results from both 2SRI and 2SLS and reported 
results from the 2SLS in this study. 
Comparison of the IVs 
We compared the performance of the two IVs based on empirical evidence of the 
assumptions of a valid IV.  First, we examined the strength of the IV by reporting F 
statistics from the first stage of the 2SLS.  A valid IV should have F statistic ≥ 10.80  A 
greater F statistic also indicates a stronger IV.  Second, we assessed the ability of both 
IVs to balance measured patient characteristics.  A stronger IV should be associated with 
fewer measured confounders.81   Finally, the assumption that a valid IV should not 
directly cause a patient outcome is not verifiable.  We adopted a method by Newhouse 
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and McClellan6 to indirectly verify this assumption.  We assessed whether the IVs were 
able to keep balance in short-term outcomes (i.e. 3-month non-vertebral fracture) that 
cannot be affected by the medical intervention (bisphosphonates).  
All analyses were performed using STATA 10. We used IVREG2 for the IV 
analysis. The study was approved by the Institutional Review Board of the University of 
Massachusetts Medical School. 
4.3 Results 
We identified 3,190 women, 50 year of age or older, who were treated by 1,678 
physicians.  The average age was 63 year old.  About 3.5% of women had a history of 
non-vertebral fracture and 29% had at least one diagnosis of osteoporosis before initiation 
of a study bisphosphonate.  The average co-morbidity score (DCG/HCC) was 
approximately 0.57.  
Table 4-1 shows the distribution of patient characteristics between women 
initiating an alendronate and those initiating a risedronate.  We found that compared with 
women initiating an alendronate those initiating a risedronate were older (62 vs. 64 years 
old; P <0.01) and had a greater co-morbidity score (DCG/HCC: 0.56 vs. 0.59; P <0.01).  
Women initiating a risedronate also more often received thyroid drugs (18.14% vs. 
21.33%; P<0.05), but less often received vitamin D (14.92% vs. 3.85%; P<0.01), 
benzodiazepine (18.83% vs. 14.57%; P<0.01) or NSAIDS/Cox-2 inhibitors (30.83% vs. 
25.64%; P<0.01).  Women initiating a risedronate were more likely located in the south 
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and in a PPO while those imitating an alendronate were more likely located in the west 
and in a HMO.  
4.3.1 Conventional Analysis 
In the conventional analysis (adjusted and unadjusted analysis for the original 
treatment assignment in Table 4- 2), we found that alendronate and risedronate had 
comparable effects on the risk of non-vertebral fractures.  The results indicated that for 
every 100 women treated with an alendronate we would expect 0.6 (RD=-0.6) fewer 
fracture cases (95%CI -2.00-1.00) had they been treated with a risedronate.  After 
adjusting for covariates, the RD reduced to -0.4 cases per 100 women and it was also not 
statistically significant.  
4.3.2 Instrumental Variable Analysis 
The IV analysis with calendar time IV (adjusted and unadjusted analyses for the 
date of generic alendronate availability in Table 4- 2) estimated that compared to 
risedronate alendronate reduced the risk of non-vertebral fractures by 2.1 cases per 100 
women (RD: -2.1; 95% CI: -8.00-4.00).  After adjusting for covariates the RD increased 
to 2.9 (RD=-2.9; 95%CI: -8.00-2.00).  Both RDs were not statistically significant.  
The IV analysis with physician preference IV (adjusted and unadjusted analyses 
for physician preference in Table 4-2) showed that compared to risedronate alendronate 
reduced the risk of non-vertebral fractures by 5.8 cases per 100 women (RD: -5.8; 
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95%CI: -12.00-1.00). In the adjusted model, the RD was -4.8 cases per 100 women 
(95%CI: -12.00-3.00).   Both RDs were not statistically significant. 
4.3.3 Comparison of the IVs: Strength of the IVs 
Table 4-3 shows the strength of the IVs in inducing the variation of the treatment 
choice.  We found that both IVs were strongly associated with the treatment choice (both 
F statistics >10). The IV1 (date of generic alendronate availability) explained more of the 
variation of the treatment choice than IV2 (physician preference) because it had a greater 
F statistic.  The F statistic for the IV1 was 200 (P<0.01) and it was 96 for IV2 (P<0.01). 
4.3.4 Comparison of the IVs: Balance of Measured Characteristics 
Tables 4-1 and 4-4 show the ability to balance measured patient characteristics 
with and without the IV1.  We found that the IV1 was associated with fewer patient 
characteristics than the original treatment assignment.  For instance, without the IV1 the 
original treatment was associated with seven patient characteristics including age, 
DCG/HCC, thyroid drug, vitamin D, benzodiazepine, NSAIDS/Cox-2 inhibitor, 
geography and health plan type.  However, the IV1 was associated with 6 patient 
characteristics including H2 inhibitor, proton pump inhibitor, vitamin D, geography, 
health plan type and mammogram.  
Tables 4-1 and 4-5 demonstrate the balance of measured patient characteristics 
with and without IV2.  The IV2 was associated with fewer patient characteristics than the 
original treatment assignment.  The original treatment assignment was associated with 
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seven patient characteristics while the IV2 was associated with 5 characteristics including 
DCH/HCC, vitamin D, benzodiazepine, geography and health plan type.  We concluded 
from Tables 4-1, 4-4 and 4-5 that both IV analyses provide better balance of patient 
characteristics than the conventional treatment analysis.   
4.3.5 Comparison of the IVs: Direct Association with the Outcome 
Table 4-6 shows the balance of 3-month non-vertebral fractures with and without 
IVs as a proxy for testing whether the IV directly causes the patient outcome.  We found 
that the 3-month non-vertebral fracture was not associated with the original treatment 
assignment, IV1 and IV2.  Compared to women initiating a risedronate those initiating an 
alendronate had a lower but not statistically significant risk of 3-month non-vertebral 
fractures (1.76% vs. 1.98; P > 0.05). Compared to women who initiated a study 
bisphosphonate before February 1st, 2008, those initiating a study bisphosphonate after 
the date had a lower but not statistically significant rate of 3-month non-vertebral 
fractures (1.89% vs. 1.73%; P >0.05).  Similarly, women whose prescribers had a 
preference of alendronate had a lower but not statistically significant rate of 3-month 
non-vertebral fractures than those whose prescribers had a preference of risedronate.  
4.4 Discussion 
In this study, we examined the comparative effectiveness of alendronate and 
risedronate on the risk of non-vertebral fractures at 12 months in women 50 years of age 
or older.  We found that conventional analyses showed no difference between the two 
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bisphosphonates in the effectiveness on the risk of non-vertebral fracture.  Compared to 
risedronate alendronate reduced the risk of 12-month non-vertebral fractures by 0.6 and 
0.4 cases per 100 women in the unadjusted and adjusted models respectively but neither 
of these effects were statistically significant.  However, since this was an observational 
study using administrative data, we were not able to adjust important patient 
characteristics such as frailty and healthy behaviors that might be associated with both 
the treatment and the outcome.  When we accounted for residual confounding from 
unmeasured variables using IV analyses we found similar results regardless of the IV.  In 
the IV analysis using calendar time IV, we found that compared to risedronate 
alendronate reduced the risk of 12-month non-vertebral fractures by 2.9 cases per 100 
women after adjusting for measured covariates and such an association was not 
statistically significant.  For another, in the analysis with the physician preference IV, we 
found that compared to risedronate alendronate had a lower but not statistically 
significant risk reduction in 12-month non-vertebral fractures (RD: -4.8; 95%CI: -12.00-
3.00).  
Previous studies have presented several IVs in prescription drug research.56, 59, 61, 
62, 64, 67  Researchers have shown that the performance of IVs varies in examining 
different questions or the same question in different populations.  For example, physician 
preference may be a strong and valid IV to assess the comparative effectiveness of 
antipsychotics in the elderly population.63  However, the IV, nursing home prescribing 
preference, performed better than physician preference in assessing the same question in 
a nursing home population.101  Understanding the practical and empirical advantages or 
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disadvantages of IVs may help researchers to solidify the validity of their IV analyses.  
Furthermore, it is unknown whether two valid IVs would have similar performance in 
addressing the same question in the same population.   
In our secondary objective to assess the performance of the two IVs, we drew the 
following conclusions.  While the overall interpretation of the IV analyses using both IVs 
did not differ from the conventional analysis, there are differences in empirical evidence 
regarding the validity of the IVs.  The calendar time IV (the date of generic alendronate 
availability) explained more of the variation of the treatment choice than did the 
physician preference IV.  The F statistic for the date of generic alendronate availability 
was 200 while it was 96 for the physician preference.  This indicated that the calendar 
time instrument might be a stronger IV than the physician preference instrument in this 
specific case.  Furthermore, a weaker IV may result in an overestimate of the true risk 
difference.101, 102  We found that the adjusted RD for the physician preference IV was -4.8 
which was greater than that found using the calendar time IV (RD=-2.8).  Finally, the IV 
estimate based on physician preference had a wider 95% confidence interval relative to 
that found based on the calendar time IV.  This effect has been seen in previous studies 
that found a wider confidence interval of the IV estimate as a consequence of applying a 
weaker IV.102 
Studies have shown that a valid IV should also balance measured patient 
characteristics.81  In our study, patient characteristics were evenly distributed with IVs.  
Fewer characteristics were significantly associated with the IVs than with the original 
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treatment.  The calendar time IV was associated with 6 measured characteristics while the 
physician preference IV was associated with 5.  This suggested that both IV were able to 
impose balance of measured patient characteristics; however, we could not rule out 
residual confounding since both IVs were still associated with some measured 
characteristics.  
Another important yet unverifiable assumption of a valid IV is that the IV should 
not directly cause a patient outcome.  As a proxy test for this assumption, we examined 
the association between the IV and a short-term outcome (3-month non-vertebral 
fractures) unaffected by the treatment as suggested by Newhouse and McClleuar.6  We 
found that both IVs were not significantly associated with 3-month non-vertebral 
fractures.  This outcome was also more evenly distributed between levels of the IVs than 
between two original treatment groups.  
In addition to the differences in empirical evidence of a valid IV, the two IVs 
differ in the application in administrative data.  Physician preference cannot be directly 
measured in administrative data.  Proxy measures103  such as the one used in this study 
requires information to identify prescribing physicians.  A previous study has shown that 
the medical license number could reliably identify the prescribing physician.104  
However, the database that captures information on the medical license number is not 
free of charge.  Furthermore, most administrative data do not have linkable information 
to the medical license number.  This may prevent researchers from applying the physician 
IV.  On the other hand, the calendar time IV, the date of generic availability, is easy to 
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apply because it does not require external data.  However, this IV is limited to 
comparison between a generic and a brand name drug.  It cannot be used to compare two 
brand name drugs. 
This study has several limitations.  First, we used data from an insured and 
employed population in the US.  The results may not be generalizable to uninsured and 
unemployed population.  In fact the IV, the date of generic availability, may perform 
better in an uninsured and unemployed population because such a population may be 
more sensitive to the price reduction of generics which may induce a greater variation in 
the choice of medication before and after the date of generic availability.  Second we 
adapted a method to measure physician preference based on our data because we did not 
have information on the prescribing physician in pharmacy claims.  This suggests that 
misclassification of the physician preference is possible.  Our proxy measure also 
resulted in the deletion of many subjects due to incomplete information.  Third, previous 
studies have shown that physician preference IV would have better performance if 
researchers only included primary care physicians because physician specialty may be a 
confounder that is associated with both the treatment choice and the patient outcome.45  
However, in our dataset we could not differentiate primary care physicians from specialty 
physicians.  This might reduce the performance of the physician preference IV in our 
study.  
Despite these limitations, our study contributes to the literature in several ways.  
First, in the absence of head-to-head trials we provided further evidence that alendronate 
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and risedronate have a comparable effect on the risk of non-vertebral fractures at 12 
months in women 50 years of age or older.  Second, we applied the IV analysis to address 
unmeasured confounding which has not been applied in previous studies examining this 
question.  Third, we applied a new calendar time IV (the date of generic availability) and 
compared it to an existing IV (the physician preference).  We found that both IVs are 
valid in this specific study based on empirical evidence of a valid IV.  Fourth, we found 
that the calendar IV was a stronger IV in explaining the variation of the treatment choice 
than the physician preference IV.  Both IVs had similar performance in reducing 
imbalance of measured patient characteristics and did not directly cause the outcome.  
Finally, the calendar IV may be more practical than the physician preference IV because 
it did not require external information to be measured accurately; thus is relatively easier 
to apply.  
In conclusion, IV analysis may be useful to estimate the comparative 
effectiveness between alendronate and risedronate on the risk of 12-month non-vertebral 
fractures in women older than 50 years. The new calendar time IV based on the date of 
generic availability appears to be valid in this specific case.  It may be practically easier 
to use the calendar time IV than the physician preference IV.  
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Women, ≥ 50 yrs, who had enrollment 
information between 2007 and 2009 
(N=8,034,624) 
Women with 1 year continuous enrollment 
before and after initiation of an alendronate 
or risedronate (N=360,857):  
Aln (n=255,612); Ris (n=105,245) 
 
Women who  
3) did not initiate an alendronate or 
risedronate  
or  
4) did not have two years continuous 
enrollment before and after the 
index date if they initiated an 
alendronate or risedronate 
 
(N=7,673,767) 
 
Women who had any 
bisphosphonates within one year 
before the index date (N=249,048) 
Aln (n=176,242), Ris (n=72,806) 
 Women who were new alendronate or 
risedronate users (N= N=111,809). 
Aln (N=79,370), Ris (N=32,439) 
 
 
Study sample (N=100,313) 
Aln=71,034; Ris=29279 
 
    
Women who had Paget’s disease or 
malignancy within a year before the 
index date (N=11,496).  
 
Study sample (N=3,190) 
Aln = 2332; Ris = 858 
 
    
Women without information on physician 
preference 
 
    
*Aln=Alendronate, Ris =Risedronate 
Figure 4-1: Sample Selection Strategy * 
 
   102 
  
Table 4-1: Distribution of Patient Characteristics Stratified by Treatment 
Assignment* 
Characteristics Alendronate Risedronate P value 
Total 2332  858   
Age (mean, sd) 62.42 (9.80) 63.77 (10.44) <0.01 
History of fracture 81 (3.47) 31 (3.61)  
Osteoporosis 683 (29.29) 228 (26.57)  
DCG/HCC (mean, sd) 0.56 (0.48) 0.59 (0.46) <0.01 
Drug that cause osteoporosis       
     Glucocorticoid 671 (28.77) 256 (29.84)  
     H2 inhibitor 108 (4.63) 39 (4.55)  
     Proton pump inhibitor 415 (17.80) 143 (16.67)  
    Thyroid drug 423 (18.14) 183 (21.33) <0.05 
Drugs that treat/prevent osteoporosis      
    Vitamin D 348 (14.92) 33 (3.85) <0.01 
    Estrogen 335 (14.37) 143 (16.67)  
    SERMS 72 (3.09) 22 (2.56)  
    Parathyroid hormone 14 (0.60) 4 (0.47)  
    Calcitonin 19 (0.81) 9 (1.05)  
Drugs associated with fracture       
    Benzodiazepine 439 (18.83) 125 (14.57) <0.01 
    SSRI/Non-SSRI 722 (30.96) 263 (30.65)  
    Anticonvulsant 183 (7.85) 68 (7.93)  
    Hypnotics 316 (13.55) 130 (15.15)  
    B blocker 472 (20.24) 190 (22.14)  
    Thiazide 221 (9.48) 83 (9.67)  
    NSAIDS/Cox-2 inhibitor 719 (30.83) 220 (25.64) <0.01 
Geography¶     <0.01 
    North Central 415 (17.80) 123 (14.34)  
,    Northeast 89 (3.82) 24 (2.80)  
    South 1093 (46.87) 590 (68.76)  
    West 733 (31.43) 120 (13.99)  
Health Plan type¶     <0.05 
    Comprehensive 86 (3.69) 31 (3.61)  
    HMO 1123 (48.16) 361 (42.07)  
    POS 131 (5.62) 59 (6.88)  
    PPO 955 (40.95) 391 (45.57)  
Health service utilization      
    Hospitalization 259 (11.11) 96 (11.19)  
    Mammogram 1353 (58.02) 466 (54.31)  
* Data are given as number (percentage) unless otherwise indicated.  
¶ Numbers do not add to 100% because of missing data 
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective 
serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory drug;  Cox-
2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of Service; 
PPO=Preferred Provider Organization 
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Table 4-2: Comparing the Effect of Alendronate vs. Risedronate on the Risk of 
Non-vertebral Fractures in 12 Month 
Unadjusted Risk difference 95%  Confidence interval 
Original treatment assignment -0.6 (-2.00-1.00) 
IV1 (date of generic availability) -2.1 (-8.00-4.00) 
IV2 (physician preference) -5.8 (-12.00-1.00) 
 
Adjusted¶   
Original treatment assignment -0.4 (-2.00-1.00) 
IV1 (date of generic availability) -2.9 (-8.00-2.00) 
IV2 (physician preference) -4.6 (-12.00-3.00) 
¶Adjusting for covariates including demographic characteristics, osteoporosis 
related factors, co-morbidity, concomitant medications, health services utilization 
region of residence and health plan types. 
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Table 4-3: Strength of the IVs in Predicting Treatment Choice* 
 Partial F statistic Partial R square P Value 
IV1 (date of generic availability) 200 0.06 <0.01 
IV2 (physician preference) 96 0.03 <0.01 
* Adjusting for covariates including demographics, osteoporosis related factors, co-
morbidity, medications, health services utilization, region of residence and health plan 
types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   105 
  
Table 4-4: Distribution of Patient Characteristics Before and After Feb, 2008* 
Characteristics Before Feb, 2008 After Feb, 2008 P value 
Total 1801  1389   
Age  (mean, sd) 62.89  (10.29) 62.64  (9.75)  
History of fracture 59 (3.28) 53 (3.82)  
osteoporosis 491 (27.26) 420 (30.24)  
DCG/HCC (mean, sd) 0.57  (0.49) 0.56  (0.46)  
Drug that cause osteoporosis      
    Glucocorticoid 527 (29.26) 400 (28.80)  
    H2 inhibitor 69 (3.83) 78 (5.62) <0.05 
    Proton pump inhibitor 291 (16.16) 267 (19.22) <0.05 
    Thyroid drug 341 (18.93) 265 (19.08)  
Drugs that treat/prevent osteoporosis      
    Vitamin D 276 (15.32) 105 (7.56) <0.01 
    Estrogen 289 (16.05) 189 (13.61)  
    SERMS 55 (3.05) 39 (2.81)  
    Parathyroid hormone 13 (0.72) 5 (0.36)  
    Calcitonin 19 (1.05) 9 (0.65)  
Drugs associated with fracture      
    Benzodiazepine 300 (16.66) 264 (19.01)  
    SSRI/Non-SSRI 551 (30.59) 434 (31.25)  
    Anticonvulsant 132 (7.33) 119 (8.57)  
    Hypnotics 238 (13.21) 208 (14.97)  
    B blocker 359 (19.93) 303 (21.81)  
    Thiazide 163 (9.05) 141 (10.15)  
    NSAIDS/Cox-2 inhibitor 506 (28.10) 433 (31.17)  
Geography¶     <0.01 
    North Central 289 (16.05) 249 (17.93)  
    Northeast 75 (4.16) 38 (2.74)  
    South 1030 (57.19) 653 (47.01)  
    West 406 (22.54) 447 (32.18)  
Health Plan type¶     <0.01 
    Comprehensive 61 (3.39) 56 (4.03)  
    HMO 729 (40.48) 755 (54.36)  
    POS 113 (6.27) 77 (5.54)  
    PPO 881 (48.92) 465 (33.48)  
Health service utilization      
    Hospitalization 192 (10.66) 163 (11.74)  
    Mammogram 981 (54.47) 838 (60.33) <0.01 
* Data are given as number (percentage) unless otherwise indicated.  
¶ Numbers do not add to 100% because of missing data 
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective 
serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory drug;  Cox-
2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of Service; 
PPO=Preferred Provider Organization 
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Table 4-5: Distribution of Patient Characteristics Stratified by Physician 
Preference* 
Characteristics Physician preference 
P 
value 
 Alendronate Risedronate  
Total 2053  1137   
Age (mean, sd) 62.35  (9.83) 63.56  (10.14)  
History of fracture 69 (3.36) 43 (3.78)  
osteoporosis 590 (28.74) 321 (28.23)  
DCG/HCC  (mean, sd) 0.56  (0.46) 0.59  (0.51) <0.01 
Drug that cause osteoporosis      
     Glucocorticoid 595 (28.98) 332 (29.20)  
     H2 inhibitor 93 (4.53) 54 (4.75)  
     Proton pump inhibitor 379 (18.46) 179 (15.74)  
    Thyroid drug 387 (18.85) 219 (19.26)  
Drugs that treat/prevent osteoporosis      
    Vitamin D 270 (13.15) 111 (9.76) <0.01 
    Estrogen 302 (14.71) 176 (15.48)  
    SERMS 59 (2.87) 35 (3.08)  
    Parathyroid hormone 13 (0.63) 5 (0.44)  
    Calcitonin 21 (1.02) 7 (0.62)  
Drugs associated with fracture      
    Benzodiazepine 402 (19.58) 162 (14.25) <0.01 
    SSRI/Non-SSRI 644 (31.37) 341 (29.99)  
    Anticonvulsant 176 (8.57) 75 (6.60)  
    Hypnotics 290 (14.13) 156 (13.72)  
    B blocker 437 (21.29) 225 (19.79)  
    Thiazide 190 (9.25) 114 (10.03)  
    NSAIDS/Cox-2 inhibitor 613 (29.86) 326 (28.67)  
Geography¶     <0.01 
    North Central 352 (17.15) 186 (16.36)  
    Northeast 83 (4.04) 30 (2.64)  
    South 962 (46.86) 721 (63.41)  
    West 653 (31.81) 200 (17.59)  
Health Plan type¶     <0.05 
    Comprehensive 84 (4.09) 33 (2.90)  
    HMO 942 (45.88) 542 (47.67)  
    POS 105 (5.11) 85 (7.48)  
    PPO 890 (43.35) 456 (40.11)  
Health service utilization      
    Hospitalization 237 (11.54) 118 (10.38)  
    Mammogram 1182 (57.57) 637 (56.02)  
* Data are given as number (percentage) unless otherwise indicated.  
¶ Numbers do not add to 100% because of missing data 
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective 
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serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory drug;  Cox-
2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of Service; 
PPO=Preferred Provider Organization 
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Table 4-6: Balance of 3-Month Non-vertebral Fracture With and Without 
IVs* 
3-month non-
vertebral fracture 
Original treatment 
Alendronate Risedronate P values 
1.76 1.98 >0.05 
IV1: date of generic availability 
Before Feb, 2008 After Feb, 2008 P value 
1.89 1.73 >0.05 
IV2: physician preference 
Alendronate Risedronate P value 
1.75 1.93 >0.05 
*IV: Instrumental variable 
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5 CHAPTER V: CONCLUSIONS 
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The objectives of this dissertation were to 1) proposed a novel IV for the 
comparative effectiveness research of prescription drugs (Chapter II); 2) explore the use 
of the IV analysis to assess the comparative effectiveness of alendronate and risedronate 
on the risk of non-vertebral fracture in older women (Chapter III) and 3) compare the 
proposed IV with an existing valid IV in order to investigate the performance of two 
individual IVs when we applied them to the same question in the same population 
(Chapter IV).  
5.1 Chapter II: Date of Generic Availability - A Potential Instrumental 
Variable in the Comparative Effectiveness Research of 
Prescription Drugs 
The objective of this study was to introduce a novel IV, the date of generic 
availability, and assess the validity of the proposed IV in a case study of bisphosphonates.  
We provided logic arguments as well as empirical evidence to support the validity of this 
IV.  The study emphasized on assessing the performance of the IV on the key 
assumptions of a valid IV.  First, we reasoned that the date of generic availability would 
be associated with patient treatment choice due to the lower price of the generic 
equivalent.  In the case study, we found that IV was strongly associated with treatment 
choice in one comparison (alendronate vs. risedronate) but not the other (alendronate vs. 
placebo). 
Second, we argued that the proposed IV was not directly and indirectly associated 
with the patient outcome except through the treatment assignment.  Since the date of 
generic availability is a calendar time IV, any residual confounding can only occur by 
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factors that vary at the exact same time as the IV.  Similarly, the date of generic 
availability is unlikely to have direct effect on patient outcomes (i.e. fracture).  In the case 
study, we demonstrated that the IV was able to balance measured patient characteristics 
implying that it could also impose balance on unmeasured confounders.  We further 
showed that the IV did not directly cause the outcome because the IV was not associated 
with the 3 month non-vertebral fracture.  Comparing with the original treatment 
assignment, the IV provided more balance of the 3 month non-vertebral fracture.   
The evidence of this study supported the validity of the date of generic 
availability as an IV in the study of bisphosphonates.  Future research is warranted to 
explore the validity of this IV in other therapeutic areas.  Furthermore, since only a 
limited number of pharmaceutical companies are allowed to manufacture the generic 
equivalents within some six months period after patent expiration, the price of such a 
generic version may not be substantially different from its brand name during the first six 
months.  As a result, the entry of generic equivalents of a brand name drug may not show 
significant impact on the treatment choice right after the patent expiration.  Future 
research may consider alternative IVs such as 6 month or even 12 months after the date 
of generic availability because it is possible that the longer a generic drug is on the 
market, the higher likelihood that patients will adopt this medication.  
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5.2 Chapter III: Comparative Effectiveness of Alendronate and 
Risedronate on Non-Vertebral Fractures: An Instrumental 
Variable Analysis 
The objective of this study was to assess the comparative effectiveness of 
alendronate vs. risedronate on the risk of non-vertebral fractures in women, 50 years of 
age or older, using claims data from multiple health plans across the US.  Since generic 
alendronate was available in February 2008 while Actonel (risedronate) is still under 
patent protection, the comparative effectiveness evidence of alendronate vs. risedronate 
on the risk non-vertebral fractures may help physicians and patients to choose a cost-
effectiveness strategy to treat osteoporosis and prevent osteoporotic fractures.  However, 
existing evidence from observational studies was inconsistent.  Possible reason of such an 
inconsistency might come from the fact that previous observational studies were not able 
to address unmeasured confounders.  Therefore, in this study we applied an IV analysis to 
address confounding from unmeasured variables beside the conventional analysis. Our 
conventional analysis showed a comparable effect of alendronate vs. risedronate on the 
risk of non-vertebral fracture at 6 months and 12 months.  The results of the IV analysis 
were consistent with those from the conventional analysis.  Therefore, our study 
supported that alendronate and risedronate were comparable to reduce the risk of 12-
month non-vertebral fractures in older women.  Since generic alendronate is availability 
on the market while generic risedronate is not, promoting the use of alendronate may help 
reduce the healthcare cost and not sacrifice the clinical effectiveness.  
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5.3 Chapter IV: Comparative Effectiveness of Alendronate and 
Risedronate on the Risk of Non-vertebral Fractures: Using Two 
Valid Instrumental Variables 
In this study, we compared the performance of two IVs (the date of generic 
alendronate availability vs. physician preference) to assess the comparative effectiveness 
of alendronate vs. risedronate on the risk of non-vertebral fractures in women 50 years of 
age or older.  We found IV analyses using both IVs reached the same conclusion that 
alendronate and risedronate were comparable to reduce the risk of non-vertebral fractures 
and these results were consistent with the conventional analysis.  However, the 
performance of the two IV was different.  Based on empirical evidence of a valid IV, we 
found that the calendar time IV explained more of the variation of the treatment choice 
than did the physician preference IV.  The physician preference IV also provided greater 
point estimates and wider confidence interval relative to the calendar time IV.  
Furthermore, both IVs could balance of measured patient characteristics.  We found that 
fewer characteristics were significantly associated with the IVs than with the original 
treatment.  However, we could not rule out residual confounding from unmeasured 
variables.  Finally, both IVs also showed indirect evidence of not being associated with 
the patient outcome.  In general, evidence supported that both IVs were valid in assessing 
the comparative effectiveness of alendronate vs. risedronate on the risk of non-vertebral 
fractures in older women.  However, the physician preference IV was a weaker IV in this 
case. 
We also evaluated the practical advantages and disadvantages of both IVs.  
Physician preference could not be directly measured in administrative data.  Proxy 
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measures such as the one used in this study requires information to identify prescribing 
physicians.  A previous study has shown that the medical license number could reliably 
identify the prescribing physician.  However, most administrative data do not have 
linkable information to the medical license number.  This may prevent researchers from 
applying the physician IV.  On the other hand, the calendar time IV, the date of generic 
availability, is easy to apply because it does not require external data.  However, this IV 
is limited to comparison between a generic and a brand name drug.  It cannot be used to 
compare two brand name drugs.  We concluded that IV analysis might be useful to 
estimate the comparative effectiveness between alendronate and risedronate on the risk of 
non-vertebral fractures in women older than 50 years. The calendar time IV based on the 
date of generic availability and the physician preference appeared to be valid in this 
specific case.  It might be practically easier to use the calendar time IV than the physician 
preference IV.  
5.4 Strengths and Limitations 
Strengths 
1. The limited existing evidence of the comparative effectiveness between 
alendronate and risedronate on the risk of non-vertebral fractures was mixed. The 
study extended the existing evidence pool. 
2. The study utilized a large nationwide sample from the MarketScan databases. The 
sample size might be more representative than those used in the previous studies. 
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3. IV analysis may provide more correct estimates because it controls for both 
measured and unmeasured confounders.  
4. The IV proposed in the study may be useful for research on other prescription 
drugs in the future. 
Limitations 
1. Although the study samples were drawn from the large convenience sample from 
large employers in the U.S., The results may not be generalizable to uninsured 
and unemployed population.  In fact the IV, the date of generic availability, may 
perform better in an uninsured and unemployed population because such a 
population may be more sensitive to the price reduction of generics which may 
induce a greater variation in the choice of medication before and after the date of 
generic availability.   
2. In Aim 1, using ICD-9 codes to identify patients with osteoporosis or at risk for 
osteoporotic fractures has not been validated in previous studies.  
Misclassification of osteoporosis patients is possible. For instance, Yood et al. 
showed that only 26% of patients (n=236) had a diagnostic code associated with 
osteoporosis after a confirmed DXA diagnosis10. In order to quantify the 
miscalculation of osteoporosis in my study, we conducted an external study to 
calculate sensitivity, specificity and positive predictive value (PPV) of 
increasingly restricted algorithms to identify patients with osteoporosis or at risk 
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for osteoporotic fractures using administrative data from the Fallon Clinic.  We 
found that the algorithm used in our study could accurately identify patients with 
osteoporosis or at risk for osteoporotic fractures (sensitivity= 71%, specificity = 
72% and PPV=76%). 
3. In Aim 3, we adapted a method to measure physician preference based on our 
data because we did not have information on the prescribing physician in 
pharmacy claims.  This suggests that misclassification of the physician preference 
is possible.  Furthermore, previous studies have shown that physician preference 
IV would have better performance if researchers only included primary care 
physicians because physician specialty may be a confounder that is associated 
with both the treatment choice and the patient outcome (cite).  However, in our 
dataset we could not differentiate primary care physicians from specialty 
physicians.  This might reduce the performance of the physician preference IV in 
our study.  
4. The use of 2SLS for a dichotomous treatment variable and outcome may have 
limitations.  Using linear models may produce expected values that are greater 
than 1 or lower than 0 and the bivariate normal distribution of errors will be 
violated.  However, researchers have suggested that this may be a theoretical 
rather than a practical problem. 105  
5. The proposed IV also has limitations.  First, this IV cannot be used in comparing 
two patent protected drugs.  Second, the strength of this IV requires further 
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examination, especially with other prescription drugs.  Our own examination 
revealed that the IV appeared to be weak when the comparator was a “placebo” 
control (no OP treatment).  A possible reason is that the prescribing pattern of OP 
treatment may not change because of the generic availability of alendronate.  
Without a strong variation in the use of alendronate overtime, the first assumption 
of a valid IV is violated.  Third, it appears that the IV, the date of generic 
availability, may perform best when there is strong evidence of confounding by 
indication; we can show that the IV not only balances observed patient 
characteristics but reduces the imbalance of these characteristics by original 
treatment groups.  Moreover, it is unnecessary to apply the IV analysis without 
strong evidence of confounding by indication.81 We suggest that research evaluate 
the performance of candidate IVs before selecting an IV for analysis.  
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6 APPENDIX 
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I. Diagnostic and procedure codes for non-vertebral fractures 
Fracture 
site 
ICD-9 ICD-9 procedure Current Procedural 
Terminology (CPT) 
Wrist  813.x, 
813.4x, 
813.5x,  
79.02, 79.12, 79.22, 
79.32 
25600, 25605, 25611, 
25620 
Hip 820.x, 
821.x 
79.x5, 79.05, 79.15, 
79.25, 79.35,  
27230-27248 
Humerus 812.20, 
812.21, 
812.30, 
812.31,  
78.12, 78.52, 79.11, 
79.21, 79.31 
24500, 24505, 24515, 
24516 
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II : Identify study drugs using national drug codes (NDC) 
Drug Name NDC 
Alendronate 
 
00006003121 00006003144 00006027044 00006071021 
00006071044 00006093628 00006093631 00006093658 
00006093672 00006093682 00006383334 00093514101 
00093514156 00093517120 00093517144 00555072051 
00555072054 00591317304 16252060102 16252060144 
16714063101 16714063102 16714063301 16714063302 
21695090204 41616063683 41616063688 41616063868 
49999050104 54569521800 54569605000 54868385700 
54868446200     54868548000  54868586100 
54868586200 55111058801 55111058830 55111059248 
58016078800 58016078830 58016078860 58016078890 
60505259301 60505259303 60505259602 60505259604 
60505259608 65862032730 65862032904 68084032264 
68258301401  
Risedronate 
 
00149047101 00149047103 00149047201 00149047204 
00149047501 16590072104 49999044804 54868438600 
54868467100   54868551800   55887068504  
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III. Identify patient characteristics using claims data 
Characteristics  Code 
  History of non-vertebral fracture See appendix I 
  Osteoporosis  ICD: 733.0x 
     Glucocorticoid Any claim within 12 month prior to the index date 
     H2 inhibior 
     Proton pump inhibitor 
    Thyroid drug 
    Vitamin D 
    Estrogen 
    SERMS 
    Parathyroid hormone 
    Calcitonin 
    Benzodiazepine 
    SSRI/Non-SSRI 
    Anticonvulsant 
    Hypnotics 
    B blocker 
    Thiazide 
    NSAIDS/Cox-2 inhibitor 
    Hospitalization Any claim 
    Mammogram ICD: V76.12; CPT: 77056 77057; HCPCS G0202 
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IV. Non-vertebral fracture between women initiating an alendronate or a risedronate, and 
between women initiating a bisphosphonate before and after generic alendronate availability 
 Fracture Alendronate Risedronate 
Before February 
1,2008 
After February 
1, 2008 
6 months Yes 1449 (2.04) 542 (1.85) 1156 (1.87) 835 (2.17) 
 No  69585 (97.96) 28737 (98.15) 60601 (98.13) 37721 (97.83) 
12 months Yes 2053 (2.89) 789 (2.69) 1661 (2.69) 1181 (3.06) 
 No  68981 (97.11) 28490 (97.31) 60096 (97.31) 37375 (96.94) 
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V: Comparing the effect of alendronate vs. risedronate on the risk of non-vertebral 
fracture in 6 months (multiple logistic regression result) 
 RD 95% confidence interval 
Alendronate vs. risedronate 0.121 -0.058 - 0.299 
Demographics     
      Age 0.041 0.032 - 0.051 
History     
     History of non-vertebral fracture 29.868 29.429 - 30.307 
     Osteoporosis  0.038 -0.130 - 0.206 
Co-morbidity (DCG/HCC) 0.701 0.506 - 0.896 
Drug that cause osteoporosis     
     Glucocorticoid -0.182 -0.370 - 0.006 
     H2 inhibior 0.015 -0.396 - 0.426 
     Proton pump inhibitor -0.064 -0.263 - 0.136 
     Thyroid drug -0.155 -0.359 - 0.049 
Drugs that treat/prevent osteoporosis     
    Vitamin D -0.436 -0.652 - -0.220 
    Estrogen -0.155 -0.390 - 0.080 
    SERMS -0.249 -0.647 - 0.150 
    Parathyroid hormone -0.671 -1.395 - 0.054 
    Calcitonin -0.350 -0.982 - 0.281 
Drugs associated with fracture     
    Benzodiazepine 0.084 -0.136 - 0.304 
    SSRI/Non-SSRI 0.497 0.307 - 0.688 
    Anticonvulsant -0.096 -0.415 - 0.222 
    Hypnotics 0.237 -0.012 - 0.486 
    B blocker -0.011 -0.214 - 0.193 
    Thiazide -0.114 -0.394 - 0.165 
    NSAIDS/Cox-2 inhibitor -0.190 -0.377 - -0.004 
Health service utilization     
    Hospitalization 1.483 1.202 - 1.763 
    Mammogram -0.251 -0.413 - -0.088 
Geography (reference=North central)     
    Northeast 0.014 -0.287 - 0.316 
    South -0.239 -1.804 - 1.326 
    West 0.013 -0.217 - 0.243 
Health Plan type (reference: 
comprehensive health plan) 
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    HMO 0.152 -0.131 - 0.435 
    POS 0.172 -0.174 - 0.518 
    PPO 0.177 -0.049 - 0.404 
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  
SSRI=selective serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-
inflammatory drug;  Cox-2=cyclooxygenase-2; HMO=Health Maintenance 
Organization; POS=Point of Service; PPO=Preferred Provider Organization 
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VI: Comparing the effect of alendronate vs. risedronate on the risk of non-vertebral 
fracture in 12 months (results from multiple linear regression) 
 
RD 95% confidence interval 
Alendronate vs. risedronate 0.096 -0.119 - 0.311 
Demographics 
    
      Age 0.080 0.068 - 0.091 
History 
    
     History of non-vertebral fracture 31.592 31.061 - 32.123 
     Osteoporosis  0.145 -0.059 - 0.348 
Co-morbidity (DCG/HCC) 1.228 0.992 - 1.464 
Drug that cause osteoporosis 
    
     Glucocorticoid -0.276 -0.504 - -0.049 
     H2 inhibior 0.152 -0.345 - 0.649 
     Proton pump inhibitor -0.140 -0.381 - 0.101 
     Thyroid drug -0.192 -0.438 - 0.054 
Drugs that treat/prevent osteoporosis 
    
    Vitamin D -0.421 -0.682 - -0.160 
    Estrogen -0.414 -0.698 - -0.130 
    SERMS -0.431 -0.913 - 0.051 
    Parathyroid hormone -0.395 -1.270 - 0.481 
    Calcitonin 0.466 -0.297 - 1.230 
Drugs associated with fracture 
    
    Benzodiazepine 0.079 -0.188 - 0.345 
    SSRI/Non-SSRI 0.790 0.560 - 1.020 
    Anticonvulsant -0.033 -0.418 - 0.352 
    Hypnotics 0.334 0.033 - 0.635 
    B blocker -0.109 -0.355 - 0.137 
    Thiazide -0.511 -0.849 - -0.174 
    NSAIDS/Cox-2 inhibitor -0.106 -0.331 - 0.120 
Health service utilization 
    
    Hospitalization 1.543 1.204 - 1.882 
    Mammogram -0.565 -0.762 - -0.368 
Geography (reference=North central) 
    
    Northeast 0.024 -0.341 - 0.388 
    South 0.039 -0.191 - 0.269 
    West -0.040 -0.319 - 0.238 
Health Plan type (reference: 
comprehensive health plan)     
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    HMO 0.053 -0.289 - 0.395 
    POS 0.084 -0.334 - 0.502 
    PPO 0.121 -0.152 - 0.395 
DCG/HCC= Diagnostic Cost Group Hierarchical Condition Category;  SSRI=selective 
serotonin reuptake inhibitor; NSAIDS=non-steroidal anti-inflammatory drug;  Cox-
2=cyclooxygenase-2; HMO=Health Maintenance Organization; POS=Point of Service; 
PPO=Preferred Provider Organization 
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